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ABSTRACT
Background
Urgent reperfusion of the occluded coronary artery halts the ischemic insult to the 
myocardium and is the single most important action to limit infarct size in ST-elevation 
myocardial infarction. However, reperfusion itself introduces an additional threat to the 
recovering ischemic myocardium whereby still viable cardiomyocytes suffer additional 
irreversible damage. This is referred to as reperfusion injury and significantly contributes 
to final infarct size. As of yet there is no established treatment to avoid or limit reperfusion 
injury, but promising results have been presented from early clinical trials of remote ischemic 
conditioning, whereby short cycles of non-harmful ischemia and reperfusion performed in 
remote tissue during the late stages of myocardial ischemia or early stages of myocardial 
reperfusion elicits an innate mechanism that ultimately terminates in cardioprotection. 
However, the exact underlying mechanisms are not fully known and additional clinical trials 
are needed to decide the possible role for remote ischemic conditioning in the treatment of 
patients with ST-elevation myocardial infarction. This thesis was undertaken to determine 
the effects of remote ischemic conditioning as an adjunct to primary percutaneous coronary 
intervention in patients with ST-elevation myocardial infarction and to explore underlying 
mechanisms.
Studies I and II
The effect of remote ischemic conditioning performed during the late stages of ischemia 
and at reperfusion as an adjunct to primary percutaneous intervention was investigated 
in 115 patients with anterior ST-elevation myocardial infarction. Infarct size as evaluated 
by cardiac magnetic resonance imaging during the first week and six months after the 
myocardial infarction, as well as clinical outcomes up to three years of follow-up were not 
affected by remote ischemic conditioning.
Study III
The involvement of the glucagon-like peptide-1 receptor in the signaling pathway of remote 
ischemic conditioning was explored in twelve healthy males. Intravenous infusion of the 
glucagon-like peptide-1 receptor antagonist exendin(9-39) abolished the protection against 
endothelial ischemia-reperfusion injury provided by remote ischemic conditioning, as 
evaluated by ultrasound based measurement of flow mediated dilatation in the brachial 
artery.
Study IV
The effect of chronic ticagrelor treatment on endothelial function was evaluated in twenty 
male patients with a previous acute coronary syndrome. Chronic ticagrelor treatment was 
not associated with protection against endothelial ischemia-reperfusion injury or better 
basal endothelial function compared to after its discontinuation, as evaluated by ultrasound 
based measurement of flow mediated dilatation in the brachial artery.
Conclusions
Remote ischemic conditioning performed during the late stages of ischemia and at reperfusion 
as an adjunct to primary percutaneous coronary intervention in patients with anterior ST-
elevation myocardial infarction does not lead to smaller myocardial infarct size or improved 
clinical outcomes. Remote ischemic conditioning utilizes a glucagon-like peptide-1 receptor 
dependent pathway to protect against endothelial ischemia-reperfusion injury. Chronic 
ticagrelor treatment does not provide protection against endothelial ischemia-reperfusion 
injury or improved basal endothelial function compared to after its discontinuation.
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SAMMANFATTNING
Trots flera decennier med stora framsteg inom forskning kring och behandling av kronisk 
kranskärlssjukdom och akut hjärtinfarkt, fortsätter dessa att vara dominerande hälsoproblem 
globalt och medför död och lidande för drabbade patienter och stora kostnader för samhället. 
Fortsatta ansträngningar för att utvidga kunskapen kring och utveckla behandlingen av dessa 
tillstånd är av största betydelse.
Riskfaktorer såsom högt blodtryck, höga blodfetter, rökning, diabetes mellitus, fetma, 
fysisk inaktivitet och ärftlighet ökar belastningen på hjärtats kranskärl och accelererar 
åderförkalkningen. De kranskärlsplack som bildas kan orsaka mer eller mindre uttalade 
förträngningar av kranskärlen. Dessa plack kan drabbas av inflammation varvid skörhet 
och sprickbildningar kan uppstå. När innehållet i ett sådant sprucket plack kommer i 
kontakt med det cirkulerande blodet aktiveras blodproppsbildande mekanismer. Den 
blodpropp som då bildas i anslutning till det spruckna placket kan leda till tilltäppning av 
det drabbade kranskärlet varvid blodförsörjningen till en del av hjärtat upphör. Till följd av 
syrebristen (ischemi) som då uppstår dör hjärtmuskelceller gradvis i det drabbade området 
- hjärtinfarkt. Om patienten överlever det akuta skedet kvarstår en ökad risk för tidig död, 
nedsatt hjärtfunktion och lidande, vilken korrelerar med utbredningen av hjärtinfarkten. För 
att begränsa celldöden och förbättra prognosen för patienten är skyndsamt återställande 
av blodflödet (reperfusion) av avgörande betydelse. Med hjälp av kateterburen teknik 
(perkutan coronar intervention - PCI) kan den tilltäppande blodproppen mekaniskt avlägsnas 
och den bakomliggande förträngningen vidgas, varvid blodflödet återställs och den skadliga 
syrebristen i hjärtmuskelvävnaden upphör. En andel av hjärtmuskelcellerna kommer därvid 
att ha drabbats av oåterkallelig skada och dött, men om blodflödet har återställts tillräckligt 
skyndsamt kommer också en andel av hjärtmuskelcellerna att ha lidit mindre uttalad syrebrist 
och endast tillfälligt skadats men med potential att återta sin funktion. Dock leder det plötsliga 
återvändandet av blodflöde även till en paradoxal negativ reaktion (reperfusionsskada) i den 
känsliga del av hjärtmuskeln som håller på att återhämta sig, varvid en andel av dessa celler 
skadas ytterligare och dör vilket resulterar i att hjärtinfarktens totala storlek blir väsentligt 
större. Det finns ännu idag ingen etablerad behandling som riktar sig mot reperfusionsskada 
trots att många olika behandlingsprinciper har utforskats extensivt, men den terapeutiska 
potentialen är stor. Den senaste tiden har dock djurstudier, experimentella mekanistiska 
studier hos människor och tidiga kliniska studier av remote ischemic conditioning (RIC) hos 
patienter med akut hjärtinfarkt visat lovande resultat. RIC bygger på princepen att korta, 
icke skadliga, cykler med ischemi och reperfusion i annan vävnad än hjärtat aktiverar ett 
kroppseget försvar som leder till skydd mot reperfusionsskada. De exakta mekanismerna 
är inte fullständigt kända, men hållpunkter för överföring av den skyddande signalen via 
nervbanor såväl som via blodet har presenterats. Syftet med denna avhandling var att 
undersöka effekten av RIC hos patienter med akut hjärtinfarkt samt att utforska möjliga 
underliggande verkningsmekanismer för skydd mot reperfusionsskada.
Studie I och II undersökte effekten av RIC (utfört genom cykler av uppblåsning av en 
blodtrycksmanschett runt ett lår) i tillägg till standardbehandling med PCI hos patienter 
med akut hjärtinfarkt. Utfallet utvärderades dels med magnetkameraundersökningar 
(cardiac magnetic resonance – CMR) inom en vecka och sex månader efter hjärtinfarkten 
och dels med analys av vårdhändelser och överlevnad upp till tre år efter hjärtinfarkten. 
Behandling med RIC resulterade inte i mindre hjärtinfarkt eller bättre hjärtfunktion akut 
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eller sex månader efter hjärtinfarkten. Inte heller noterades bättre överlevnad eller mindre 
hjärt-kärlsjuklighet upp till tre år efter hjärtinfarkten.
Studie III undersökte betydelsen av glukagon-lik peptid-1 (GLP-1) för den skyddande 
effekten av RIC mot reperfusionsskada. En modell av tillfällig reperfusionsskada på blodkärl 
(endotelial reperfusionsskada) i underarmen användes och utvärderades med hjälp av 
ultraljudsundersökning av blodkärlsfunktionen (flödesmedierad dilatation - FMD). GLP-1 
receptorhämmaren exendin(9-39) blockerade den skyddande effekten av RIC mot endotelial 
reperfusionsskada.
Studie IV undersökte om långtidsbehandling med det blodplättshämmande läkemedlet 
ticagrelor skyddar mot reperfusionsskada eller medför bättre blodkärlsfunktion 
(endotelfunktion) jämfört med efter behandlingens avslut. Ticagrelor ingår som 
standardbehandling under en begränsad tidsperiod efter akut hjärtinfarkt. Tidigare studier 
har föreslagit att preparatet förutom sin blodplättshämmande effekt kan ha ytterligare 
skyddande effekter på hjärta och blodkärl genom alternativa verkningsmekanismer. 
Patienter med tidigare hjärtinfarkt och pågående behandling med ticagrelor studerades 
i en underarmsmodell av endotelfunktion baserad på ultraljudsmätning av FMD. 
Långtidsbehandling med ticagrelor resulterade inte i skydd mot endotelial reperfusionsskada 
eller bättre endotelfunktion jämfört med efter behandlingens utsättande.
Resultaten i denna avhandling:
1. Stödjer inte hypotesen att RIC skyddar hjärtat mot reperfusionsskada vid akut hjärtinfarkt, 
till skillnad från vad tidigare studier har antytt. För att bättre förstå denna skillnad i 
utfall behövs stora studier fokuserade på robusta utfallsmått och fortsatt utforskande av 
underliggande verkningsmekanismer för RIC.
2. Illustrerar utmaningen i att överföra fynd från djurstudier och experimentella mekanistiska 
studier hos människa till kliniska studier hos patienter med akut hjärtinfarkt.
3. Visar att RIC skyddar mot endotelial reperfusionsskada genom en GLP-1 receptorberoende 
mekanism hos människa, vilket indikerar att GLP-1 är involverad i RIC-medierat skydd mot 
reperfusionsskada. Detta är en helt ny kunskap som förtjänar att studeras närmare och 
erbjuder nya infallsvinklar och möjligheter att förstå verkningsmekanismen bakom RIC.
4. Visar att långtidsbehandling med ticagrelor hos patienter med tidigare hjärtinfarkt inte 
skyddar mot endotelial reperfusionsskada eller förbättrar endotelfunktionen jämfört med 
efter dess utsättning.
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ABBREVIATIONS AND ACRONYMS
AAR area at risk
ACE-I angiotensin converting enzyme-inhibitor
ACh acetylcholine
ACS acute coronary syndrome
ADP adenosine diphosphate
AKI acute kidney injury
Akt protein kinase B
ANOVA analysis of variance
APPROACH Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease
ARB angiotensin II receptor blocker
ATP adenosine triphosphate
AUC area under curve
BARI Bypass Angioplasty Revascularization Investigation
BMI body mass index
BSA body surface area
CABG coronary artery bypass grafting
cAMP cyclic adenosine monophosphate
CGRP calcitonin gene-related peptide
CI-AKI contrast-induced acute kidney injury
CKMB creatine kinase-myocardial band
CMR cardiac magnetic resonance
CRP C-reactive protein
DBP diastolic blood pressure
ECG electrocardiogram
EIVD endothelium-independent vasodilatation
eNOS endothelial nitric oxide synthase
ENT1 equilibrative nucleoside transporter 1
ERK extracellular regulated kinase
ESA endocardial surface area
ESC European Society of Cardiology
FMD flow-mediated dilatation
FU follow-up
GFR glomerular filtration rate
GLP-1 glucagon-like peptide-1
GP-IIb/IIIa glycoprotein IIb/IIIa
GSK3β glycogen synthase kinase 3β
HDL high-density lipoprotein
HF heart failure
HOMA-IR Homeostatic Model Assessment of Insulin Resistance
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IR ischemia-reperfusion
IS infarct size
JAK Janus kinase
LAD left anterior descending artery
LDL low-density lipoprotein
LGE late gadolinium-enhancement
LV left ventricle
LVEDV left ventricular end-diastolic volume
LVEF left ventricular ejection fraction
LVESV left ventricular end-systolic volume
MACCE major adverse cardiac and cerebrovascular events
MaR myocardium at risk
MBG myocardial blush grade
MI myocardial infarction
mPTP mitochondrial permeability transition pore
MSI myocardial salvage index
MVO microvascular obstruction
NO nitric oxide
PCI percutaneous coronary intervention
PI3K phosphatidylinositol 3-kinase
PKA protein kinase A
PKC protein kinase C
PKG protein kinase G
PLATO Platelet Inhibition and Patient Outcomes
RCA right coronary artery
RIC remote ischemic conditioning
RISK Reperfusion Injury Salvage Kinase
ROS reactive oxygen species
SAFE Survivor Activator Factor Enhancement
SBP systolic blood pressure
SDF-1 stromal cell-derived factor-1
SEM standard error of the mean
SPECT single photon emission computed tomography
SR sarcoplasmic reticulum
STEMI ST-elevation myocardial infarction
TG triglycerides
TIMI Thrombolysis In Myocardial Infarction
TnI troponin I
TnT troponin T
TTE transthoracic echocardiogram
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INTRODUCTION
Sudden obstruction of a coronary artery caused by thrombotic occlusion at the site of a 
ruptured atherosclerotic plaque leads to ischemia and subsequent ST-elevation myocardial 
infarction (STEMI) (Figure 1). Urgent restoration of coronary blood flow by primary 
percutaneous coronary intervention (PCI) is the cornerstone of modern STEMI treatment 
and limits the extent of the myocardial infarction1. However, reperfusion itself introduces 
an additional threat to the myocardium, whereby ischemic but still viable cardiomyocytes 
at the end of ischemia are  further injured by the return of blood flow2. This is referred 
to as reperfusion injury and is sometimes divided into four types: 1) myocardial stunning 
– transient dysfunction of previously ischemic but not irreversibly injured myocardium; 
2) no-reflow phenomenon – paradoxical absence of coronary reflow in the infarct-related 
artery despite technically successful intervention towards the culprit lesion; 3) reperfusion 
arrhythmias – disturbances of cardiac rhythm occurring after successful reperfusion of the 
occluded coronary artery; 4) lethal reperfusion injury – cardiomyocyte death occurring after 
successful reperfusion of ischemic myocardium. Lethal reperfusion injury may contribute to 
as much as 50 % of the final infarct size (Figure 1)3.
Figure 1. Ischemia-reperfusion injury in STEMI. A) ECG showing STEMI. B) STEMI is typically 
caused by acute thrombotic coronary occlusion at the site of a ruptured atherosclerotic 
plaque. C) Ischemia occurs in the myocardial area supplied by the occluded coronary vessel 
(dark red). D) Urgent reperfusion by primary PCI relieves ischemia and limits the extent 
of the myocardial infarction. Part of the ischemic myocardium has suffered irreversible 
ischemic injury and cardiomyocyte death (dark grey). A proportion of the ischemic 
myocardium is still alive at reperfusion (bright grey), but suffers additional damage from 
the return of blood flow – reperfusion injury - leading to enlargement of the infarcted 
myocardial area. ECG = electrocardiogram; PCI = percutaneous coronary intervention; 
STEMI = ST-elevation myocardial infarction.
         Cardioprotection through remote ischemic conditioning
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In this thesis, the term ischemia-reperfusion injury will be used to refer to lethal reperfusion 
injury. There is still no established therapy to restrict reperfusion injury, but the large 
therapeutic potential is evident (Figure 2).
Over the latest decades intense research has focused on finding ways to limit the extent 
of ischemia-reperfusion injury. While several different concepts have been explored, the 
technique of eliciting innate cardioprotective mechanisms through intermittent short cycles 
of ischemia and reperfusion in remote tissue - remote ischemic conditioning (RIC) has 
emerged as one of the most promising evolving strategies. However, clinical data are scarce 
and not entirely conclusive and the underlying mechanisms are far from fully understood.
Acute myocardial infarction
Prolonged strain from risk factors such as hypertension, hyperlipidemia, smoking, diabetes 
mellitus, obesity, physical inactivity and hereditary factors contributes to the formation of 
coronary atherosclerotic plaques and development of ischemic heart disease (IHD)4-6. IHD 
is a dominant health problem worldwide, leading to extensive morbidity, mortality and 
cost to society7. The Global Burden of Disease study estimated that IHD was prevalent in 
more than 110 million people and accounted for close to nine million deaths worldwide 
Figure 2. Ischemia-reperfusion injury. Shortly after coronary occlusion (black arrow) ischemic 
cardiomyocyte death ensues and the extent increases with time. Urgent reperfusion (red 
arrow), preferably with PCI limits ischemic cell death and the extent of myocardial infarction. 
However, although ischemia is relieved, cell death does not cease immediately at reperfusion 
as additional damage is conferred by reperfusion injury (yellow field), substantially contributing 
to final infarct size. A hypothetical cardioprotective approach directed towards reperfusion 
injury (green arrow) has the potential to significantly reduce final infarct size. Solid black 
line indicates progressing ischemic myocardial injury. Dashed black line indicates maximal 
extent of myocardial ischemic injury if no reperfusion is achieved. Red line indicates course of 
reperfusion injury. Green line indicates theoretical course in the event of effective intervention 
against reperfusion injury. PCI = percutaneous coronary intervention. (Adapted from Garcia-
Dorado, Piper. Cardiovasc Res. 2006 Jan;69(1):1-3.)
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in 20158. In its most acute form, coronary artery disease culminates in rupture of the 
atherosclerotic coronary plaque leading to the formation of an occlusive coronary thrombus 
(Figure 1)9-11. The resulting transmural ischemia is typically manifested as acute chest pain 
and ST-segment elevation on the electrocardiogram (ECG). Extensive cardiomyocyte cell 
death spreads according to the wavefront phenomenon12,13 and the risk of acute mortality 
is considerable. For patients surviving the acute phase, the risk of disabling chronic heart 
failure is substantial and correlates to myocardial infarct size14. Extensive research over the 
last decades has introduced several efficient cardioprotective strategies aimed at limiting 
the ischemic burden on the myocardium and counteracting the thrombotic activation1. 
Beta-blockers are beneficial as they decrease myocardial oxygen demand by reducing blood 
blood pressure, heart rate and myocardial contractility, while dual antiplatelet therapy 
with aspirin and a P2Y12 inhibitor (preferably ticagrelor) is the recommended mode of 
platelet inhibition. Importantly, the single most effective action to limit the final infarct size 
is to rapidly restore coronary blood flow. In some settings without access to acute cardiac 
catheterization, primary reperfusion is attempted with fibrinolytic compounds. However, 
coronary revascularization is most efficiently achieved through urgent primary PCI. PCI is 
typically performed by advancing a coronary guide catheter through the radial artery, to 
reach the ostium of the occluded coronary artery. Then, a coronary guidewire is passed 
through the coronary guide catheter, further on in to the coronary artery of interest and 
through the occlusion. Subsequently a coronary dilatation balloon is advanced over the 
coronary guidewire to the site of coronary occlusion, where it is inflated to remove the 
occlusion and dilate the underlying ruptured atherosclerotic plaque, thereby typically 
achieving restoration of coronary blood flow and instant relief of the ischemic threat to the 
myocardium. The procedure is typically concluded with the placing of a coronary stent over 
the ruptured coronary plaque in a similar manner. To maximize the gain of primary PCI it is 
important to avoid any time delay and guidelines set ≤90 minutes from first medical contact 
to reperfusion as a quality target15.
Reperfusion injury
Since the first description of myocardial reperfusion injury in 1960 by Jennings et al.16, 
extensive research has revealed a complex system of events initiated upon restoration 
of blood flow that may further hurt the ischemic heart. While the ultimate endpoint of 
reperfusion injury is cardiomyocyte death, several cell types are involved in reperfusion 
injury. Under physiological conditions as well as in the ischemia-reperfusion setting the 
cardiomyocytes are in deep interaction with the abundant endothelial cells lining the 
extensive vascular network surrounding the cardiomyocytes17. These endothelial cells in 
turn have an intense interplay with cells and molecules circulating in the vessels. While 
the exact mechanism of reperfusion injury still is partly unknown, several important steps 
have been identified. Opening of the mitochondrial permeability transition pore (mPTP) is a 
crucial event, leading to mitochondrial swelling and cell death (Figure 3)18.
Reoxygenation
Upon reoxygenation of the ischemic (but still not irreversibly injured) myocardium an array of 
intracellular processes are initiated that terminate in hypercontracture of myofibrils, damage 
to the cell membrane and cell death. The cardiomyocyte accumulates Ca2+ and Na+ in the 
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cytosol during ischemia19,20. At reoxygenation, the Ca2+ pump of the sarcoplasmic reticulum 
(SR) is reactivated to clear Ca2+ from the cytosol into the SR21,22. As the large amounts of Ca2+ 
exceed the storage capacity of the SR, a continuous oscillating state of intake and release of 
Ca2+ is reached, which in turn induces malicious hypercontracture of the cardiomyocytes as 
well as opening of mPTPs23. The latter is considered a key event, leading to collapse of the 
inner mitochondrial membrane potential, uncoupling of oxidative phosphorylation, energy 
depletion, mitochondrial swelling and cell death18. Furthermore, Ca2+ overload activates 
calpains which degrade the cytoskeleton and damage the Na+ pump of the cell membrane, 
further contributing to cell injury24. This additionally contributes to Ca2+ overload as an intact 
function of the Na+ pump of the cell membrane is important to uphold a proper Na+ gradient 
to the extracellular compartment, which is required by the Na+/Ca2+ exchanger of the cell 
membrane in order to relieve the excess Ca2+ 22. Moreover, the cytoskeleton of the recently 
ischemic cardiomyocyte is hypersensitive to the forceful contractions of the myofibrils due 
to Ca2+ overload and upon re-energization the cell is prone to go into a deleterious state of 
irreversible hypercontracture25.
In addition, upon reoxygenation there is a massive increase of reactive oxygen species 
(ROS) which are formed in cardiomyocytes, endothelial cells and infiltrating neutrophils26. 
The large amounts of ROS that are generated widely exceed the capacity of endogenous 
scavenging systems. ROS exert several detrimental effects via the reduction of bioavailability 
of nitric oxide (NO), opening of mPTP and further attraction of neutrophils and activation of 
platelets and complement that all contribute to myocardial injury27,28. 
Restoration of pH
Reperfusion of the occluded artery leads to rapid correction of the acidic extracellular 
milieu, leading to a massive H+ gradient over the cardiomyocyte membrane. Subsequently 
the Na+/H+ exchanger and the Na+/HCO
3
- co-transporter are activated to quickly correct this 
Figure 3. Simplified scheme of key mechanisms involved in the cardiomyocyte in 
reperfusion injury. NO = nitric oxide; mPTP = mitochondrial permeability transition pore; 
ROS = reactive oxygen species ; SR = sarcoplasmic reticulum.
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imbalance29. However, these events have negative consequences as the sudden restoration 
of pH leads to withdrawal of the inhibitory effect of acidosis on the hypercontraction-prone 
myofibrils. In addition, the inflow of Na+ may exceed the capacity of the Na+ pump in the 
cell membrane to maintain an adequate Na+ gradient for the Na+/Ca2+ exchanger to function 
properly, leading to reversal of its mode with resulting Ca2+ inflow to the cardiomyocyte, 
further exacerbating the negative consequences of Ca2+ overload.
Restoration of tissue osmolality
Reperfusion of the occluded artery also causes rapid correction of the hyperosmolar 
extracellular environment, leaving a substantial gradient to the still hyperosmolar 
cardiomyocyte due to accumulation of Na+ and anaerobic metabolites30. This leads to rapid 
inflow of water and swelling of the fragile hypercontracting postischemic cell which causes 
further cell damage and disruption of the cell membrane.
Remote ischemic conditioning
The concept of ischemic conditioning whereby innate organ protective properties are 
activated by short non-harmful cycles of ischemia and reperfusion before, during or 
shortly after the deleterious long period of ischemia and subsequent reperfusion has been 
extensively explored since the first demonstration of ischemic conditioning by Murry et 
al. three decades ago31. They showed that brief intermittent occlusions of the left anterior 
descending artery (LAD) prior to a prolonged infarct-generating occlusion and subsequent 
reperfusion of the same vessel was cardioprotective in dogs. While the efficacy of ischemic 
pre-conditioning has been consistent over a large number of species32, this approach is 
applicable only in situations where ischemia and reperfusion is planned, and hence not an 
alternative in the STEMI-setting in which the ischemic insult cannot be foreseen. However, 
it is also possible to achieve similar protection by performing the conditioning stimulus 
immediately after the deleterious ischemic insult and during the initial phase of reperfusion3. 
This approach is more compatible with the STEMI-setting, where such ischemic post-
conditioning can be performed locally in the infarct related artery by short re-occlusions 
of the vessel during PCI. Several clinical studies of such local ischemic post-conditioning in 
patients with STEMI have been performed, but results have been inconclusive33. Another way 
to induce ischemic conditioning is by performing the conditioning stimulus in tissue distant 
to the area at risk – remote ischemic conditioning (RIC). This was initially demonstrated by 
Przyklenk et al. who performed the conditioning stimulus in the circumflex artery in dogs 
to limit the extension of the infarcted area following occlusion of the LAD34. In fact, the 
conditioning stimulus can even be performed in a remote organ, as originally described by 
Gho et al.35. It has been demonstrated in numerous animal studies that brief repetitive cyles 
of ischemia and reperfusion in remote tissue such as in the limbs, kidneys, intestines, skin 
and brain induce protection in the heart. Furthermore, the RIC-stimulus can be performed 
before (remote ischemic preconditioning), during (remote ischemic perconditioning) or 
after (remote ischemic postconditioning of the deleterious ischemic period in a manner 
similar to that demonstrated in local conditioning procedures36. Mechanistic studies in 
humans using surrogate markers have shown that this mechanism exists in humans37 and 
early studies of RIC as an adjunct to PCI in patients with STEMI have shown promising results 
which are described in detail below38-48. The exact mechanism by which RIC leads to end 
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organ protection is far from fully understood but there is evidence for humoral49 as well as 
neural involvement49-54. The general idea is that RIC initiates a remote signal (neural or/and 
humoral) that is transmitted (neurally or/and humorally) to the end organ where it induces 
protection.
RIC-mechanisms
While the exact way by which RIC leads to end-organ protection still is unknown, a common 
approach is to separate the mechanism into (1) initiation of a conditioning stimulus by RIC 
in a remote organ, (2) transfer of the conditioning signal to the end-organ and (3) exertion 
of end-organ protection (Figure 4).
Figure 4.  Simplified schematic overview of proposed transmission of the RIC signal. 
Cycles of ischemia and reperfusion in remote tissue initiate a conditioning signal that 
is transmitted through a neurohumoral interplay to reach the heart. There it activates 
cardioprotection, predominatly through inhibition of the mitochondrial permeability 
transition pore. Proposed contributors to signaling are presented, but the precise 
mechanism is not fully known. Red arrow denotes the RISK (Reperfusion Injury Salvage 
Kinase) pathway. Blue arrow denotes the PKG (protein kinase G) pathway. Green arrow 
denotes the SAFE (Survivor Activator Factor Enhancement) pathway. Akt = protein kinase 
B; cAMP = cyclic adenosine monophosphate; CGRP = calcitonin gene-related peptide; 
eNOS  endothelial nitric oxide synthase; ERK = extracellular regulated kinase; GLP-1 = 
glucagon-like peptide-1; GSK3β = glycogen synthase kinase 3β; JAK = Janus kinase; NO = 
nitric oxide; PI3K = phosphatidylinositol  (4,5)-bisphosphate 3-kinase; PKA = protein kinase 
A; PKC = protein kinase C; PKG = protein kinase; RIC = remote ischemic conditioning; SDF-
1 = stromal cell-derived factor-1; STAT = signal transducer and activator of transcription. 
Adapted from Heusch. Circ Res. 2015;116:674-699 and Hausenloy, Yellon. Nat Rev Cardiol. 
2016 Apr;13(4):193-209.
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(1) Initiation of a conditioning stimulus by RIC
The nature of the conditioning stimulus that is created by short cycles of ischemia and 
reperfusion is still unknown. However, there is strong evidence that this stimulus activates 
nerve fibers within the conditioned tissue, to relay the signal further, as demonstrated by 
the findings that sectioning of sciatic and femoral nerves abolishes cardioprotection induced 
by RIC in the limb55-57. While several endogenous compounds have been suggested to be 
released in peripheral tissue in response to RIC, considerable attention has been focused 
on adenosine58,59 and bradykinin60 acting as autacoids, either activating afferent nerve fibers 
to further relay the conditioning signal or stimulating the release of other humoral factors.
(2) Transfer of the conditioning signal to the end-organ
The involvement of a blood-borne factor carrying the conditioning signal is strongly 
supported by the fact that plasma dialysate from a conditioned individual contains a 
conditioning stimulus that can be successfully transferred to another individual to provide 
cardioprotection61-63. This can even be done across species64. In addition, a transplanted 
denervated heart can be protected from ischemia-reperfusion injury by RIC65. Extensive 
efforts have been made to identify a humoral factor involved in transferring the conditioning 
signal. This factor is suggested to be of lower molecular weight than 15 kDa61 and there 
is support for the involvement of several possible factors, such as nitrite66, stromal cell-
derived factor-167 and microRNA-14468. Thus, while the precise nature of this humoral 
transfer still is not known, it is likely that the mechanism is complex and involves several 
steps including an intricate interplay with the neural system. This is supported by the 
finding that the possibility to transfer cardioprotection through plasma dialysate from a 
conditioned individual is lost if the donor suffers from diabetic neuropathy49 or has been 
vagotomized53. In addition, cardioprotection by RIC can be blocked by the autonomic 
ganglion blockers hexamethonium35,53 and trimetaphan37 and by the muscarinic receptor 
blocker atropine50,52,53. Further evidence for the critical involvement of the neural system 
is that sectioning of the spinal cord or the vagal nerve abolishes cardioprotection provided 
by RIC50,57. Indeed, there is accumulating evidence for the crucial involvement of the vagal 
nerve and recent data show that selective sectioning of the posterior gastric branch of the 
vagal nerve inhibits cardioprotection by RIC, while electrical stimulation of the same branch 
affords cardioprotection69. As the posterior gastric branch of the vagal nerve modulates 
release of glucagon-like peptide-1 (GLP-1)70,71, this merits further interest as it links RIC to 
the established cardioprotective properties of GLP-172-76.
While there is evidence for a combined neurohumoral pathway transferring the 
cardioprotective signal, the exact mode of interaction between the neural and humoral 
components as well as their communication with the end-organ remains elusive. The heart 
receives abundant innervation which could be responsible for relaying the cardioprotective 
signal to the cardiomyocytes77. This view has been challenged by the fact that RIC induces 
cardioprotection in isolated heart models such as Langendorff-perfused preparations61. 
However, these hearts retain their extensive intrinsic cardiac innervation including local 
neural loops which regulate cardiac function78. The involvement of the intrinsic cardiac 
innervation in RIC is indicated by the finding that the cardioprotective effect on an isolated 
heart of dialysate from a conditioned individual is lost in the presence of the ganglion 
blockers hexamethonium and atropine53. It has been suggested that a humoral factor 
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may activate these intrinsic cardiac circuits to induce end-organ protection53. However, 
the indispensability of intrinsic neural involvement has been questioned by the finding 
that isolated cardiomyocytes are protected from ischemia-reperfusion injury by dialysate 
from conditioned rabbits in an opioid receptor-dependent manner61,79. Furthermore, an 
interaction with adenosine receptors seems to be present79. Whether acting via the intrinsic 
cardiac innervation or not, additional studies support adenosine58,80,81 and opioids82,83 as 
possible end-organ effectors. In addition, several other ligands have been explored84, of 
which bradykinin60,85 and calcitonin gene related peptide86 have received the most attention.
(3) Exertion of end-organ protection
Final exertion of cardioprotection in RIC is a complex, multifactorial and not fully understood 
matter. The general view is that the conditioning signal reaches the cardiomyocyte and 
activates intracellular protective kinases that exert protection mainly through effects on the 
mitochondria, primarily by inhibiting the deleterious opening of the mPTP which is central 
to reperfusion injury (Figure 4)84,87. In addition, there is evidence for involvement of the 
endothelium37, anti-inflammatory effects88 and decreased thrombotic activity28 in exerting 
the full cardioprotective effect of RIC.
RIC in STEMI
The simple application of RIC using a blood pressure cuff inflated above systolic blood 
pressure (SBP) has made it feasible to implement into clinical studies. Over the last few 
years several clinical studies investigating the efficacy of RIC have been performed which 
indicate that RIC may have a place as an adjunct to primary PCI in STEMI (Table I).
The first study of the effect of RIC in patients with STEMI was presented by Bøtker et al. 
in 201038. Four cycles of RIC of the upper limb before PCI was associated with a larger 
myocardial salvage index (MSI) compared to standard therapy as measured by single 
photon emission computed tomography (SPECT). In addition, a follow-up study showed that 
major adverse cardiac and cerebrovascular events (MACCE) were reduced89. Rentoukas et 
al. found that ST-resolution was improved and peak troponin I levels were decreased by 
three cycles of RIC of the upper limb during late ischemia and early reperfusion in patients 
with STEMI39. In addition, the effect was more pronounced by simultaneous infusion of 
morphine. Similar findings were presented by Crimi et al.40. Three cycles of RIC of the lower 
limb initiated at coronary reperfusion improved ST-resolution and lowered levels of creatine 
kinase-myocardial band (CKMB) in patients with STEMI. However, in a subgroup of patients 
undergoing cardiac magnetic resonance (CMR), infarct size was unchanged. White et al. used 
CMR to measure myocardial infarct size as primary outcome in a trial evaluating the effect 
of four cycles of RIC of the upper limb prior to primary PCI in patients with STEMI41. Their 
main finding was that absolute infarct size was reduced. However, also myocardial edema 
determined by CMR, which is considered to reflect MaR, was smaller in the intervention 
group. Thus CMR based MSI was not significantly different between study groups, which 
somewhat complicates the interpretation. However, “hybrid MSI” based on infarct size from 
CMR and MaR from angiographic scores was improved in the RIC group. Three cycles of 
lower limb RIC starting at reperfusion with primary PCI did not affect the primary outcome 
LVEF or left ventricular remodeling at 6 months as assessed by echocardiography in a trial 
by Elbadawi et al.46. Likewise, peak CKMB was neutral between study groups, but a better 
ST-resolution was noted in the RIC group. Liu et al. utilized CMR to show less microvascular 
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obstruction, smaller absolute infarct size and better acute LVEF in response to four cycles of 
RIC of the upper arm during ambulance transport to primary PCI45. Additionally, peak CKMB 
was lower in the RIC group and myocardial blush grade was higher. However, no effect on 
ST-resolution was noted. Lower peak CKMB and 72 h area under curve CKMB together with 
less acute kidney injury and better LVEF after seven days was reported from Cao et al. in 
response to four cycles of RIC of the upper arm, starting within one minute of reperfusion 
by primary PCI47. Similarly, Yamanaka et al. found lower peak CKMB and less acute kidney 
injury together with less tendency for ventricular arrhythmias in a group of patients 
receiving three cycles of RIC of the upper arm before primary PCI44. However, LVEF assessed 
by echocardiography two weeks after the STEMI was not affected. Using a protocol of three 
cycles of RIC of the lower limb during late ischemia and early reperfusion in 448 patients 
with STEMI undergoing primary PCI, Gaspar et al. found that patients in the RIC group had 
lower incidence of the combined primary endpoint of cardiac mortality and hospitalization 
for heart failure as well as for the individual components48. Additionally, the incidence of 
acute heart failure was lower in the RIC group and patients with more severe heart failure 
had better recovery of left ventricular function at one year follow-up. 
It has also been hypothesized that the combination of different interventional strategies such 
as remote and local conditioning may have additive effects. Prunier et al. found that three 
cycles of upper limb RIC before PCI reduced CKMB levels but adding local postconditioning 
to the protocol had no effect42. Eitel et al. showed that three cycles of upper limb RIC prior to 
PCI combined with local postconditioning in the infarct related artery in patients with STEMI 
resulted in a greater MSI when compared to standard therapy as measured with CMR43. 
Additionally, a reduced incidence of major adverse cardiac events (driven by lower rate of 
heart failure) over a median of 3.6 years follow-up was demonstrated90. However, the effect 
of RIC alone was not studied in this trial.
Adding RIC to thrombolysis has also been investigated. Four cycles of upper arm RIC initiated 
before reperfusion with streptokinase resulted in lower 24 h area under curve CKMB and 24 
h area under curve troponin T91. 
Thus, RIC in adjunction to primary PCI in STEMI has shown promising results in early studies, 
but as presented in Table II, the picture is not entirely conclusive. While several of the 
studies have indicated a positive effect of RIC using absolute measures of infarct size as 
primary endpoints, markers of infarct size taking into consideration MaR have been more 
difficult to interpret. Furthermore, all studies so far have been too limited in sample size 
for proper evaluation of hard clinical outcomes. Nonetheless, these early data indicate that 
RIC may have cardioprotective properties in patients with STEMI. Considering the huge 
potential clinical benefit if proven to protect against reperfusion injury in patients with 
STEMI, further studies based on robust measures of infarct size and clinical outcomes in 
large sample studies are warranted. Of additional importance, the most solid support for 
the effect of RIC in STEMI comes from the trial by Bøtker et al., in which RIC was initiated in 
the ambulance and completed before reperfusion therapy38. However, in several settings the 
prerequisites for such a setup may be lacking (for instance very short ambulance transport, 
less coordinated prehospital organization or patients arriving to the hospital by other means 
of transport than ambulance). In those cases, a RIC-protocol needs to be initiated at arrival 
in the catheterization laboratory but completed during PCI in a per-post design including the 
final conditioning cycles after reperfusion to avoid delaying reperfusion.
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Myocardium at risk
The use of absolute infarct size as endpoint in clinical studies of cardioprotection against 
ischemia-reperfusion injury has the limitation that it is sensitive to several factors, some of 
which are difficult to control for (e.g. localization of coronary occlusion, temporal variation 
of degree of coronary occlusion, extent of collaterals and TIMI-flow). The consequence of 
this is a substantial variability in absolute infarct size within the study groups and thus need 
for large sample sizes in trials based on absolute infarct size as primary outcome measure. 
To overcome this, infarct size may be evaluated in relation to the MaR in each subject92. 
MaR refers to the ischemic myocardial area at risk for irreversible injury from ischemia-
reperfusion. Coronary angiography provides the possibility to evaluate MaR using models 
based on the location of the culprit lesion and distribution of the coronary arteries. Several 
such models have been developed and provide prognostic information93,94. However, these 
scores are anatomically based assumptions of extent of ischemia rather than measurements 
of actual ischemia in each subject. The gold standard for evaluation of MaR in clinical 
studies of myocardial ischemia-reperfusion injury is SPECT95-97, which is based on the lack 
of uptake and accumulation of isotope in non-perfused myocardial areas during coronary 
occlusion. However, SPECT requires injection of the isotope prior to coronary reperfusion 
and subsequent imaging within a few hours, which impairs its usefulness under certain 
circumstances. Additionally it exposes the patient to radiation. More recently, CMR-based 
techniques to evaluate MaR have gained increased popularity as they do not risk impairing 
the acute management of patients and offer a more convenient time window for performing 
the examination. CMR provides the possibility to determine MaR and infarct size in a single 
examination within a week from the myocardial infarction. Evaluation of MaR based on the 
endocardial extent of infarction (endocardial surface area (ESA) method))94 has been used 
in studies of cardioprotection98. However, this method may underestimate MaR especially 
in cases with successful cardioprotective intervention99. Most utilized methods to evaluate 
MaR by CMR are essentially based on detection of myocardial edema. In the ischemia-
reperfusion setting several mechanisms contribute to the formation of edema100. The major 
constituent of the myocardium is water, most of it being intracellular and predominantly 
bound to proteins and other molecules. Within a few minutes of ischemia, edema of the 
cardiomyocyte occurs due to failure of the Na+/K+ pump with subsequent accumulation of 
intracellular Na+ and increased osmotic pressure leading to increase of intracellular water 
content. Furthermore, ischemia-induced acidosis leads to conformational changes of water-
binding molecules, resulting in release of bound water. Additionally, prolonged ischemia 
causes damage to capillary membranes, resulting in leakage of water from the intravascular 
to the interstitial space. Moreover, reperfusion of the ischemic myocardium substantially 
contributes to myocardial edema. Reperfusion leads to rapid restoration of extracellular 
osmotic pressure, increase of extracellular water content and subsequently through 
osmotic pressure also increase of intracellular edema. The degree of water content in the 
myocardium is reflected in CMR-imaging and additionally the distinct properties of free vs 
bound water are manifested. Thus, the extent of myocardial edema as evaluated by CMR is 
a convenient surrogate marker for MaR. T1- and T2-weighted imaging reliably depict MaR 
up to one week after the myocardial infarction101,102. Contrast-enhanced steady state free 
precession imaging provides superior image quality to T2-weighted imaging and has been 
validated against SPECT103 and angiographic scores104. Still, there has been some debate 
regarding the validity of CMR based evaluation of MaR105,106 and the most appropriate timing 
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Table II. Variables in studies of RIC as an adjunct to primary PCI in STEMI. MaR on CMR is edema-based. 
MSI on CMR is derived from IS and edema-based MaR. Hybrid MSI is derived from IS and angiographically 
determined MaR. Green box indicates a positive effect of RIC. Blue box indicates a neutral effect of RIC. 
Yellow box indicates somewhat complex interpretation of the variable. Grey box indicates that the variable 
was not evaluated or clearly reported. # indicates the primary endpoint of the trial. 
AUC = area under curve; CKMB = creatine kinase-myocardial band; CMR = cardiac magnetic resonance; FU = 
follow-up; GFR = glomerular filtration rate; HF = heart failure; IS = infarct size; LV = left ventricle; LVEF = left 
ventricular ejection fraction; MaR = myocardium at risk; MBG = myocardial blush grade; MSI = myocardial 
salvage index; MVO = microvascular obstruction; SPECT = single photon emission computed tomography TnI 
= troponin I; TnT = troponin T; TTE = transthoracic echocardiogram.
Variables Bøtker38 Rentoukas39 Crimi40 Prunier42 White41 Yamanaka44 Verouhis Liu45 Elbadawi46 Cao47 Gaspar48
Cardiac 
enzymes
TnT Peak or point
AUC
TnI Peak or point
AUC
CKMB Peak or point
AUC # #
ST-resolution #
CMR IS #
FU IS
MSI #
FU MSI
Hybrid MSI
MaR
MVO #
SPECT IS
MSI #
MaR
LV parameters 
from CMR or 
TTE
LVEF #
LV size
LV recovery at FU #
Renal function #
Angiographic TIMI-flow
MBG
Clinical Early combined
Late combined #
Early HF
Late HF
Comments
Subgroup 
analysis of 
cases with 
large MaR 
showed more 
pronounced 
effect on 
MSI, better 
LV function 
acutely and 
persisting 
at 30 days 
for the RIC 
group.
Smaller extent 
of myocardial 
edema in the 
RIC group. No 
effect on renal 
function overall 
but for patients 
with low pre-
procedural GFR, 
RIC was associ-
ated with lower 
postprocedural 
creatinine.
CKMB AUC 
was not 
significantly 
reduced. 
CKMB AUC/
AAR however 
was. Adding 
local postcon-
ditioning to 
the protocol 
did not alter 
outcomes.
Smaller 
extent of 
myocardial 
edema in 
the RIC 
group. TnT 
was lower 
at 24 h but 
not at other 
time points.
MaR was larger 
in the RIC group.
Not clear what 
were primary 
and secondary 
outcomes.
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Table II. Variables in studies of RIC as an adjunct to primary PCI in STEMI. MaR on CMR is edema-based. 
MSI on CMR is derived from IS and edema-based MaR. Hybrid MSI is derived from IS and angiographically 
determined MaR. Green box indicates a positive effect of RIC. Blue box indicates a neutral effect of RIC. 
Yellow box indicates somewhat complex interpretation of the variable. Grey box indicates that the variable 
was not evaluated or clearly reported. # indicates the primary endpoint of the trial. 
AUC = area under curve; CKMB = creatine kinase-myocardial band; CMR = cardiac magnetic resonance; FU = 
follow-up; GFR = glomerular filtration rate; HF = heart failure; IS = infarct size; LV = left ventricle; LVEF = left 
ventricular ejection fraction; MaR = myocardium at risk; MBG = myocardial blush grade; MSI = myocardial 
salvage index; MVO = microvascular obstruction; SPECT = single photon emission computed tomography TnI 
= troponin I; TnT = troponin T; TTE = transthoracic echocardiogram.
Variables Bøtker38 Rentoukas39 Crimi40 Prunier42 White41 Yamanaka44 Verouhis Liu45 Elbadawi46 Cao47 Gaspar48
Cardiac 
enzymes
TnT Peak or point
AUC
TnI Peak or point
AUC
CKMB Peak or point
AUC # #
ST-resolution #
CMR IS #
FU IS
MSI #
FU MSI
Hybrid MSI
MaR
MVO #
SPECT IS
MSI #
MaR
LV parameters 
from CMR or 
TTE
LVEF #
LV size
LV recovery at FU #
Renal function #
Angiographic TIMI-flow
MBG
Clinical Early combined
Late combined #
Early HF
Late HF
Comments
Subgroup 
analysis of 
cases with 
large MaR 
showed more 
pronounced 
effect on 
MSI, better 
LV function 
acutely and 
persisting 
at 30 days 
for the RIC 
group.
Smaller extent 
of myocardial 
edema in the 
RIC group. No 
effect on renal 
function overall 
but for patients 
with low pre-
procedural GFR, 
RIC was associ-
ated with lower 
postprocedural 
creatinine.
CKMB AUC 
was not 
significantly 
reduced. 
CKMB AUC/
AAR however 
was. Adding 
local postcon-
ditioning to 
the protocol 
did not alter 
outcomes.
Smaller 
extent of 
myocardial 
edema in 
the RIC 
group. TnT 
was lower 
at 24 h but 
not at other 
time points.
MaR was larger 
in the RIC group.
Not clear what 
were primary 
and secondary 
outcomes.
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for it, considering the bimodal pattern of edema after myocardial infarction107-110. However, 
a recent study in pigs validated contrast-enhanced steady state free precession imaging and 
T2-weighted imaging against histopathology to measure MaR seven to ten days after LAD 
artery occlusion and found good agreement, confirming its applicability in this time frame111.
The endothelium
The human arterial wall is a three-layered structure. The media is separated from the outer 
adventitia and the inner intima by the external and internal elastic membranes and consists 
mainly of a layer of smooth muscle cells surrounded by extracellular matrix. The external 
adventitia is a collagen-rich connective tissue embedding the nervous (nervi vasorum) 
and vascular (vasa vasorum) supply of the artery. The intima consists of a single layer of 
endothelial cells, the endothelium, supported by loose connective tissue.
The endothelium is a highly active physiological entity with several important features. It 
is involved in the regulation of vascular tone and permeability, vessel wall inflammatory 
mediators and hemostasis112. The endothelium exerts its physiological properties mainly 
through endocrine and paracrine mediators. NO is the most extensively investigated 
endothelium derived factor113. It is formed from the amino acid L-arginine under the action 
of endothelial nitric oxide synthase (eNOS) and mediates several cardinal functions of the 
endothelium. However, endothelial function is not consistent. Aging as well as common 
conditions such as atherosclerosis, diabetes mellitus, hypertension, hyperlipidemia, obesity 
and smoking lead to impaired endothelial function related to reduced bioavailability of 
NO, owing to its reduced synthesis and increased degradation114. Furthermore, endothelial 
dysfunction provides prognostic information as it is associated with progression of 
atherosclerosis and predicts future cardiovascular clinical events115. Interestingly, endothelial 
dysfunction is an important event in development of myocardial ischemia-reperfusion injury 
during myocardial infarction by contributing to inflammation and oxidative stress116,117.
Assessment of endothelial function was originally derived from the response to intracoronary 
infusion of acetylcholine (Ach)118. Under normal conditions, coronary arteries respond to this 
stimulus by dilatation due to release of NO. In patients with coronary artery disease however, 
endothelial dysfunction is manifested as impaired coronary dilatation or even paradoxical 
vasoconstriction. However, such assessment of the coronary arteries is an invasive and 
somewhat cumbersome technique and alternative approaches have been developed that 
correlate well to coronary endothelial function. Ultrasound-based measurement of flow-
mediated dilatation (FMD) of the brachial artery utilizes the phenomenon that increased 
blood flow after temporary noninvasive occlusion of the upper arm leads to shear stress 
and endothelial release of NO leading to vasodilatation under normal conditions119,120. Apart 
from evaluating basal endothelial function, FMD can be used to test the effect of acute or 
chronic interventions on endothelial function and as such it is commonly used as a convenient 
surrogate marker for clinical events37,121,122. Furthermore, endothelial function is temporarily 
impaired by a limited period of ischemia followed by reperfusion123. It may therefore serve 
as a model for studies of ischemia-reperfusion injury. FMD can thus be used to measure the 
degree of such endothelial ischemia-reperfusion injury and evaluate the effect of interventions 
directed against it122-124.
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Glucagon-like peptide-1
The incretin hormone glucagon-like peptide-1 (GLP-1) is derived from proglucagon, 
primarily released by the L-cells of the small intestine, but noteworthy also from neurons in 
the nucleus of the solitary tract of the brainstem125. GLP-1 controls blood glucose levels by 
regulating the release of insulin and glucagon in response to intake of food. GLP-1 receptor 
agonists have been increasingly used over the last decade for the treatment of diabetes 
mellitus and have been shown to decrease all-cause mortality, cardiovascular mortality and 
the rates of myocardial infarction and stroke126,127. However, the effects of GLP-1 receptor 
agonists are not restricted to the control of blood glucose levels. Animal studies have shown 
that GLP-1 receptor agonists attenuate ischemia-reperfusion injury72,74,128. Furthermore, 
infusion of the GLP-1 receptor agonist exenatide in non-diabetic patients undergoing 
primary PCI for STEMI has been demonstrated to confer cardioprotection75,76 and this effect 
is irrespective of baseline blood glucose levels, showing that the mechanism is not related 
to control of acute hyperglycaemia129. Interestingly, the release of GLP-1 is modulated by the 
vagal nerve71 which is also suggested to be involved in RIC52, thereby indicating a possible 
link between those two cardioprotective approaches.
Ticagrelor
Rupture of an atherosclerotic plaque in the acute coronary syndrome (ACS) exposes 
circulating platelets to the subendothelium130. Thereby a complex multifactorial 
prothrombotic avalanche is triggered including interaction with subendothelial proteins such 
as von Willebrand factor and collagen, adhesion of platelets to the vessel wall and release 
of prothrombotic factors from platelet granules resulting in recruitment and reshaping 
of additional platelets, activation of the coagulation cascade and formation of a growing 
and potentially occluding vascular thrombus131 leading to STEMI. Adenosine diphosphate 
(ADP) is one of the major prothrombotic factors released from platelet granules during this 
process132. ADP is formed by dephosphorylation of adenosine triphosphate (ATP) and stored 
in dense granules in the platelets. Upon release, ADP interacts with the platelet surface 
bound G-protein coupled purinergic P2Y
12
 receptor to further promote platelet aggregation, 
largely through phosphatidylinositol 3-kinase (PI3K) dependent pathways. To counteract the 
deleterious drive for coronary thrombosis associated with ACS, dual antiplatelet therapy 
is recommended133. In addition to cyclooxygenase inhibition by aspirin, the directly acting 
reversible P2Y
12
 receptor inhibitor ticagrelor is preferred after showing superiority to 
clopidogrel in the PLATO trial134. Following an acute loading dose, guidelines recommend 
continuous treatment for one year. Prolonged duration of ticagrelor treatment is considered 
for certain high-risk individuals. However, this recommendation is primarily based on 
one large randomized trial showing a modest risk-benefit gain135. Importantly, underlying 
mechanisms for this prolonged protection are poorly understood, but actions beyond 
platelet inhibition have been suggested136. Apart from its antithrombotic P2Y
12
 receptor-
dependent properties, ticagrelor is also an inhibitor of adenosine reuptake through the 
equilibrative nucleoside transporter 1 (ENT1) in the cardiomyocyte cell membrane, resulting 
in increased extracellular levels of adenosine and thereby adenosine-related pleiotropic 
cardiovascular effects137,138. This is of potential interest as there is evidence for adenosine-
induced protection against ischemia-reperfusion injury139,140. In fact, ticagrelor has been 
shown to confer cardioprotection in animal studies of ischemia-reperfusion in an adenosine-
dependent manner141-144. Whether ticagrelor protects against ischemia-reperfusion injury in 
humans has not been investigated previously.
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Summary
Reperfusion injury is a major contributor to final infarct size in STEMI. As of yet, there is 
no established therapy directed towards reperfusion injury. The concept of protecting 
against reperfusion injury through RIC as an adjunct to primary PCI has shown promising 
results in early studies, but the overall picture is not entirely conclusive and the underlying 
mechanisms are not fully known. Additional trials based on robust endpoints are needed to 
establish the role for RIC in STEMI. Further exploration of the underlying mechanisms may 
give the prerequisites to take full advantage of the underlying therapeutic potential.
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AIMS
The overall aim of this thesis was to evaluate the effect of RIC in patients with STEMI and to 
explore the underlying mechanisms of RIC in humans. The specific aims were to investigate if:
1. RIC confers cardioprotection when provided in addition to primary PCI in patients 
with STEMI (Study I and II)
2. The effect of RIC on endothelial ischemia-reperfusion injury in humans involves 
activation of the GLP-1 receptor (Study III)
3. Treatment with ticagrelor is associated with protection against endothelial 
ischemia-reperfusion injury and improved endothelial function in patients with a 
previous ACS (Study IV)
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METHODS
All studies were approved by the regional ethics committee in Stockholm and conducted 
according to the Declaration of Helsinki145.
Study subjects
Studies I and II
Consecutive patients arriving to any of the including hospitals (Karolinska University 
Hospital Solna, Karolinska University Hospital Huddinge, Södersjukhuset and Danderyd 
Hospital, all in Stockholm, Sweden) with signs and symptoms of anterior STEMI were 
screened for participation. Inclusion criteria were chest pain indicating myocardial ischemia 
with a duration >30 minutes and <6 hours, ST-elevation >0.1 mV (>0.2 mV in V2-V3) in two 
contiguous leads (V1-V6) and age over 18 years. Exclusion criteria were previous myocardial 
infarction, left bundle branch block, previous coronary artery bypass grafting, cardiac arrest, 
severe claudication, atrial fibrillation, treatment with glibenclamide or cyclosporine, any 
condition that may interfere with the possibility for the patient to comply with the study 
protocol or PCI not performed. After informed oral consent patients were entered into the 
study. Completive written consent was acquired within 24 hours.
Study III
Healthy male adults were eligible for the study and recruited through posts on announcement 
boards at Karolinska Institutet and through telephone calls to previous participants in 
medical trials. After oral and written information, written consent was acquired and patients 
were entered into the study.
Study IV
Consecutive eligible male patients with a recent ACS awaiting their one-year clinical follow-
up visit at Karolinska University Hospital Solna, Karolinska University Hospital Huddinge or 
Danderyd Hospital were identified from the follow-up part of the SWEDEHEART (Swedish 
Web-system for Enhancement and Development of Evidence-based care in Heart disease 
Evaluated According to Recommended Therapy) registry146. The registry was at the time 
containing all patients age ≤75 years treated for an ACS in Sweden. Inclusion criteria were 
ACS within one year and ongoing ticagrelor treatment planned for discontinuation according 
to clinical guidelines. Patients with diabetes mellitus were excluded from the study. Patients 
were contacted through telephone calls and after oral and written information, written 
consent was acquired and patients were entered into the trial.
Study design
Studies I and II
The trial was performed as a multicenter randomized controlled trial with blinded evaluation. 
After informed consent, eligible patients fulfilling inclusion but not exclusion criteria were 
randomized 1:1 to receive RIC or sham procedure. Randomization was computer-generated 
in blocks of eight. RIC was performed by inflating a blood pressure cuff around the left thigh 
to 200 mmHg (or 20 mmHg above SBP if SBP was above 180 mmHg) for five minutes and 
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then deflating, with a new cycle starting five minutes after deflation. RIC started immediately 
after randomization. At least one cycle was to be completed before first coronary balloon 
inflation and another four cycles thereafter (Figure 5). 
Inflations of the blood pressure cuff were performed through an automated device (PeriVasc 
Cuff Unit, EBIDA, Göteborg, Sweden). Sham procedure was performed by placing the blood 
pressure cuff around the left thigh, without inflating it.
PCI was performed according to local guidelines. Double antiplatelet therapy was given 
with aspirin (500 mg) and ticagrelor (180 mg) or clopidogrel (600 mg) in the ambulance 
or at arrival at the catheterization laboratory. Additional medication and interventional 
considerations were according to clinical guidelines and at the discretion of the PCI operator.
Venous blood samples for analyses of high sensitivity troponin T were collected on admission, 
after six and twelve hours and then every eight hours until 44 hours from inclusion.
Patients underwent a first CMR (see below for detailed protocol) four to seven days after the 
PCI and a second CMR six months later. Follow-up of clinical data up to three years after the 
event was through patient charts, registries and telephone calls to patients.
Study III
Examinations took place in the morning. Subjects were overnight fasting and refraining 
from tobacco products. For the main study, subjects were examined with three different 
protocols (A-C) on three separate occasions with at least six days between visits (Figure 6).
Figure 5. Protocol for Studies I and II. Dashed square indicates additional conditioning 
cycles performed before PCI if time allowed. CMR = cardiac magnetic resonance imaging; 
PCI = percutaneous coronary intervention; RIC = remote ischemic conditioning.
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The order of the protocols was randomized for each subject. In protocol A, FMD was 
examined in the left brachial artery (see below for detailed description) before and after 
20 minutes of ischemia followed by 20 minutes of reperfusion to measure the degree of 
endothelial impairment induced by ischemia-reperfusion. In protocol B, FMD was tested 
before and after 20 minutes of ischemia and 20 minutes of reperfusion with simultaneous 
RIC to evaluate its conditioning effect. In protocol C, FMD was performed before and after 20 
minutes of ischemia and 20 minutes of reperfusion with simultaneous RIC and intravenous 
infusion of the GLP-1 receptor antagonist exendin(9-39) (Bachem, Bubendorf, Switzerland) 
to explore the impact of GLP-1 receptor inhibition. In an additional protocol (D), FMD was 
examined before and after 40 minutes infusion of exendin(9-39) to evaluate its effect on 
FMD per se (no ischemia-reperfusion was performed in this protocol).
Endothelium-independent vasodilatation (EIVD) was evaluated at the end of each protocol 
by performing an additional FMD-measurement after sublingual administration of 0.4 mg 
nitroglycerine.
Figure 6. Protocol for Study III. Protocol A = Ischemia-reperfusion. Protocol B = Ischemia-
reperfusion + RIC. Protocol C = Exendin(9-39) + ischemia-reperfusion + RIC. Protocol D = 
Exendin(9-39). FMD = flow-mediated dilatation; GLP-1 = glucagon like peptide 1; RIC = 
remote ischemic conditioning.
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Ischemia-reperfusion was performed by inflating a blood pressure cuff around the left upper 
arm to 200 mmHg for 20 minutes and then deflating it for 20 minutes of reperfusion.
RIC was performed by inflating a blood pressure cuff around the left thigh to 200 mmHg for 
five minutes and then deflating, with a new cycle starting five minutes after deflation. Four 
such cycles (two during ischemia and two during reperfusion) were performed (Figure 7).
Exendin(9-39) was administered through a cannula in a superficial vein in the right antecubital 
fossa. A bolus of 7500 pmol/kg was given 10 minutes before the first FMD measurement 
followed by infusion of 500 pmol/kg/min throughout the protocol. This dose is known to 
antagonize the effect of GLP-1 in humans147,148.
Venous blood samples for analysis of plasma GLP-1 were collected before forearm ischemia 
and one minute and 16 minutes after start of reperfusion. Venous blood samples for 
analysis of plasma insulin were collected in EDTA tubes before baseline FMD and at the end 
of reperfusion.
Study IV
Examinations took place in the morning. Patients were overnight fasting and refraining from 
tobacco products, but were instructed to take their morning medication (1-2 hours before 
examinations). Each patient was examined on three occasions with identical protocols 
(Figure 8).
Figure 7. Setup for Study III. FMD was evaluated by ultrasound in the left brachial artery after 
inflation (200 mmHg for five minutes) and deflation of a blood pressure cuff around the upper 
part of the left forearm. Ischemia-reperfusion was achieved by inflating a blood pressure cuff 
around the left upper arm to 200 mmHg for 20 minutes followed by 20 minutes reperfusion 
by deflating the cuff. RIC was performed by inflating a blood pressure cuff around the left thigh 
to 200 mmHg for five minutes and then deflating, with a new cycle starting five minutes after 
deflation. FMD = flow-mediated dilatation; RIC = remote ischemic conditioning.
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The first visit (A) coincided with the last day of the twelve month ticagrelor treatment after 
ACS, after which the drug was discontinued according to clinical indication. Another two 
visits (B and C) followed with an interval of two to four weeks between each visit. FMD was 
examined in the left brachial artery before and after 20 minutes of arm ischemia followed 
by 20 minutes of reperfusion as described for Study III above.
EIVD was evaluated at the end of each protocol by performing an additional FMD-
measurement after sublingual administration of 0.4 mg nitroglycerine. Venous blood 
samples were collected at the beginning of each visit for analyses of platelet inhibition.
CMR
CMR examinations were performed at the Karolinska University Hospital using a 1.5 T 
Siemens Magnetom Aera scanner (Siemens Healthcare, Erlangen, Germany) in Studies I and 
II. A gadolinium-based contrast agent (Gd-DTPA, 0.2 mmol/kg, Dotarem, Guerbet, France) 
was used. ECG-gated images in 12-14 short axis views (eight mm thickness, two mm gap) 
and in the two-, three- and four-chamber views were acquired during breath-holds. For 
determination of MaR, early contrast-enhanced steady state free precession images were 
obtained. For quantification of infarct size, late gadolinium-enhancement (LGE) images were 
collected 15 to 20 minutes after contrast injection using an inversion recovery gradient echo 
sequence. Segment v1.9 R3967 (http://segment.heiberg.se) was used for offline analyses of 
images149. Epi- and endocardial borders were manually outlined on short axis stacks of early 
contrast-enhanced steady state free precession and LGE images. MaR was manually outlined 
on early contrast-enhanced steady state free precession sequences150. The automated Otsu 
quantification method151 with weighted approach152 and manual adjustments where needed 
was used to determine infarct size and microvascular obstruction. Two observers blinded to 
randomization performed individual analyses of CMR images, followed by final co-evaluation 
to reach consensus. Intra-observer variability for MaR and infarct size determinations were 
0.9 ± 2.3% and 0.5 ± 1.6% (bias and SD), respectively.
Figure 8. Protocol for Study IV. An identical protocol was used for all three visits. The first 
visit was at the end of the planned 12-month period of ticagrelor treatment, after which 
the drug was discontinued. The second and third visits were two and four week after 
discontinuation of ticagrelor treatment. EIVD = endothelium-independent vasodilatation; 
FMD = flow-mediated dilatation.
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Angiographic evaluation
TIMI blood flow153 in the infarct related artery before and after coronary intervention and 
the presence of collaterals according to the Rentrop classification154 was evaluated by the 
PCI operator. Two experienced interventional cardiologists blinded to the randomization 
evaluated MaR according to BARI (Bypass Angioplasty Revascularization Investigation)93 and 
modified APPROACH (Alberta Provincial Project for Outcome Assessment in Coronary Heart 
Disease)94 scores.
FMD
FMD was performed with a Vivid E9® (GE, Waukesha, Wisconsin, USA) and an 11MHz (output 
12MHz) linear-array transducer mounted on a flexible arm for stabilization. End-diastolic 
baseline artery diameter was recorded every 3 seconds for 1 minute and a mean value was 
calculated. A blood pressure cuff was inflated to 200 mmHg for five minutes around the 
upper part of the left forearm and the deflated. The brachial diameter was continuously 
recorded for three minutes after deflation and a mean diameter was calculated from the 
three frames with maximal dilatation at end-diastole155. Diameter was measured intima-
intima and FMD was calculated as: diameter following cuff deflation – baseline diameter 
∕ baseline diameter × 100. Peak blood flow velocity during hyperemia was recorded with 
pulsed Doppler and a mean from three cardiac cycles was calculated. A technician blinded 
to the protocol performed evaluations. Intra-observer variability for FMD was 0.1 ± 3.9 (bias 
and SD).
Biochemical analysis
Blood samples for the analysis of plasma GLP-1 were immediately placed in tubes containing 
the dipeptidyl peptidase 4 inhibitor diprotin (final concentration 0.1 mmol/L) to avoid 
cleavage. Plasma GLP-1 was analyzed with ELISA No EZGLP1T (Merck), measuring total GLP-1 
(both the active form (7-36) and fragments of GLP-1)156. The same lot was used for all samples. 
The intra-assay variation is <5%. Plasma insulin was analyzed by electrochemiluminescence 
immunoassay. Blood samples for the analysis of platelet inhibition were collected in Hirudin-
containing tubes and analyzed within two hours using impedance aggregometry (Multiplate, 
Roche Diagnostics)157. The effect of ticagrelor and aspirin was evaluated with the ADP-test 
(platelet function after stimulation of platelet adenosine diphosphate receptors) and ASPI-
test (platelet function stimulated by arachidonic acid) respectively. Simultaneous analysis 
was performed to confirm platelet counts above 50 x 109/L (using EDTA containing tubes).
Statistical analysis
GraphPad Prism version 6.05 for Windows (GraphPad Software, La Jolla, CA, USA) was used 
for statistical analysis.
Studies I and II
The primary endpoint of Study I was myocardial salvage index (MSI) defined as 100 × (MaR-
infarct size)/MaR. Power size calculation assuming a relative reduction of infarct size in 
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relation to MaR of 30% (based on a relative reduction of 50% of infarct size in relation to 
MaR in patients with LAD occlusions in a previous study of RIC38) and an SD of 0.66 using 
log transformed data (based on a previous study, quantifying infarct size and MaR with 
CMR158), 88 patients were needed to achieve 80% power and a statistical level of 0.05. To 
compensate for non-parametric tests, dropouts and poor CMR image quality, an additional 
30% of patients were planned to be included. Secondary outcomes included major adverse 
cardiovascular events within 30 days, infarct size according to high sensitivity troponin T 
and infarct size on CMR according to absolute values. As Study II was a follow-up study of 
Study I, it did not have a separate power calculation. Its primary endpoint was MSI at 6 
months (using infarct size from the second CMR and MaR from the first CMR). Secondary 
CMR-based outcomes were final absolute infarct size and left ventricular ejection fraction 
(LVEF). Secondary clinical endpoints were analyzed up to three years after the event and 
included cardiac mortality, MACCE (composite of all-cause mortality, myocardial infarction, 
readmission for heart failure, ischemic stroke (including transient ischemic attack) and target 
lesion revascularization) and all the individual components of MACCE. Non-parametric 
Mann-Whitney U-test was used for continuous variables and Fisher’s exact test for 
categorical variables. Intra-observer variability was evaluated with Bland-Altman analysis. 
Data are presented as medians and interquartile ranges if not otherwise indicated.
Study III
The primary endpoint was change in FMD from baseline following ischemia-reperfusion. 
Assuming a relative improvement in FMD of 30% (based on our own pilot studies), 12 
subjects were needed to achieve 80% power at a significance level of 0.05. To compensate 
for examinations with poor image quality and for possible dropouts, fourteen subjects 
were recruited. Normality of data was tested using D’Agostino and Pearson normality 
test. One-way ANOVA was used for comparison of treatment effect and two-way ANOVA 
for comparison of FMD and plasma levels of GLP-1 between baseline and after ischemia-
reperfusion and between groups. Intra-observer variability was tested with Bland-Altman 
analysis. Data are presented as means ± SEM if not otherwise indicated.
Study IV
The primary endpoint of the study was change in FMD from baseline to after ischemia-
reperfusion. Based on our previous studies of protection against endothelial ischemia-
reperfusion injury159,160, an absolute improvement in FMD of 1.3 % was estimated. Thus, 
with a standard deviation of 1.8%, 15 patients were needed for 80 % power at a significance 
level of 0.05. To compensate for possible dropouts and for examinations with poor image 
quality, 20 volunteers were recruited. Normality of data was tested using D’Agostino and 
Pearson normality test. Ischemia-reperfusion induced change in FMD at each visit was 
analyzed with paired t-test. Platelet inhibition, basal endothelial function and endothelial 
ischemia-reperfusion injury was compared between visits with one-way ANOVA and Tukey’s 
multiple comparisons post-hoc test was used where appropriate. Intra-observer variability 
was tested with Bland-Altman analysis. Data are presented as means ± SEM or medians and 
interquartile ranges if not otherwise indicated.
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RESULTS
Study groups
Studies I and II
Out of 594 consecutive patients screened for participation, 150 fulfilled the entry criteria 
and could be randomized to RIC or sham procedure (Figure 9).
Thirty-five patients were excluded during hospital stay, leaving 115 patients in the per-
protocol analysis of Study I. For the long term follow-up of Study II, survival data were 
available for 113 patients as one patient withdrew consent and one patient was lost to 
follow-up. 93 patients completed a first CMR examination of sufficient quality for analysis 
of the primary endpoint of Study I and 76 of those patients underwent a second CMR 
examination after six months for analysis of the primary endpoint of Study II (Figure 10).
Figure 10.  Anterior myocardial infarction on CMR imaging in Studies I and II. MaR with contrast-
enhanced steady state free precession from CMR imaging 4-7 days after STEMI (left). Myocardial 
scar with LGE from CMR imaging 4-7 days after STEMI (center). Myocardial scar with LGE from 
CMR imaging 6 months after STEMI (right). Blue arrow indicates microvascular obstruction present 
on early CMR but not on follow-up examination. CMR = cardiac magnetic resonance; LGE = late 
gadolinium enhancement; MaR = myocardium at risk; STEMI = ST-elevation myocardial infarction.
Figure 9. Patient flow chart in Studies I and II. CABG = coronary artery bypass grafting; CMR 
= cardiac magnetic resonance; PCI = percutaneous coronary intervention; RIC = remote 
ischemic conditioning.
Eligible
n=594
Excluded during hospital stay 20
PCI not performed
- No culprit lesion 6
- Acute CABG 2
Discomfort from blood pressure cuff 6
Violation to protocol 5
Unknown reason for exclusion 1
Randomized
n=150
Inclusion criteria not 
fulfilled or exclusion
criteria met
n=444
PCI + RIperpostC
n=80
RIperpostC group
n=60
PCI
n=70
Excluded during hospital stay 15
PCI not performed
- No culprit lesion 9
Violation to protocol 5
Withdrawn consent 1
PCI group
n=55
Complete CMR data at first week 47
Complete CMR data at six months 36
Clinical follow-up up to three years 59
Complete CMR data at first week 46
Complete CMR data at six months 40
Clinical follow-up up to three years 54
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Baseline and periprocedural characteristics were overall well balanced between the groups 
(Table III and Table IV), although the RIC group had a notably higher prevalence of smokers 
and occlusions of the proximal LAD.
Table IV. Periprocedural characteristics of patients included in analysis of MSI on CMR at day 4-7 in 
Study I. Data are presented as median and interquartile range or number of subjects and percentages 
except for number of remote ischemia cycles performed which is presented as median and total 
range. Significant differences were analyzed using Mann-Whitney U-test and Fisher´s exact test. CMR 
= cardiac magnetic resonance; GP-IIb/IIIa = glycoprotein IIb/IIIa; LAD = left anterior descending artery; 
MSI = myocardial salvage index; PCI = percutaneous coronary intervention; RCA = right coronary 
artery; RIC = remote ischemic conditioning; TIMI = Thrombolysis In Myocardial Infarction.
Variables PCI (n=46) RIC+PCI (n=47)
Periprocedural medication
Ticagrelor 43 (93) 46 (98)
Clopidogrel 27 (59) 24 (51)
Bivalirudin 41 (89) 41 (87)
GP-IIb/IIIa inhibitor 5 (11) 3 (6)
Morphine 42 (91) 40 (85)
Angiographic and interventional variables
Radial access 39 (85) 38 (81)
Culprit vessel
LAD
Proximal LAD
Circumflex
RCA
42 (91)
11 (24)
2 (4)
2 (4)
46 (98)
18 (38)
0 (0)
1 (2)
TIMI 0-1 flow on presentation 42 (91) 39 (83)
TIMI 2-3 flow on presentation 4 (9) 8 (17)
Rentrop score 0 38 (83) 36 (77)
Rentrop score 1 5 (11) 6 (13)
Rentrop score 2 4 (9) 5 (11)
Thrombus aspiration performed 8 (17) 10 (21)
Direct stenting performed 6 (13) 9 (19)
Number of remote ischemia cycles 
performed N/A 7 (5-11)
Table III. Baseline characteristics of all patients in Studies I and II. Data are presented as median 
and interquartile range or number of subjects and percentages. Significant differences were 
analyzed using Mann-Whitney U-test and Fisher’s exact test. PCI = percutaneous coronary 
intervention; RIC = remote ischemic conditioning.
Variables PCI (n=55) RIC+PCI (n=60)
Age, years 63 (57-69) 62 (53-68)
Men 52 (95) 54 (90)
Symptom to balloon time, min 158 (115-252) 145 (122-203)
Current smoker 16 (29) 30 (50)
Current treatment for hypertension 15 (27) 12 (20)
Current treatment for dyslipidemia 3 (5) 4 (7)
Previously known diabetes mellitus 6 (11) 6 (10)
Killip class 1 52 (95) 54 (90)
         Cardioprotection through remote ischemic conditioning
39
Study III
Fourteen volunteers underwent protocol A-C in the main part of the study. Two of those 
subjects were excluded due to insufficient image quality of the FMD registration. Eleven 
subjects (nine of which had also participated in protocol A-C) were examined with protocol 
D. Study subjects had a mean age of 30.5 (range 19-48) years and a body mass index of 24 
± 0.7. Mean fasting glucose was 5.1 ± 0.1 and Homeostatic Model Assessment of Insulin 
Resistance (HOMA-IR) 1.5 ± 0.3. All study subjects self-assessed their exercise capacity 
as normal or good. Two subjects were smokers and one subject reported regular intake 
of dietary supplements (vitamin C and omega 3). The examination protocols were well 
tolerated by all subjects.
Study IV
Twenty patients with a mean age of 60 (range 40-74) years were recruited. Baseline 
characteristics of the patients are shown in Table V. Examinations with insufficient image 
quality or motion artefacts were excluded. Seventeen patients at each visit remained for 
final analysis of FMD.
Table V. Baseline characteristics of patients in Study IV. Medians and interquartile ranges 
or numbers and percentages. n=20. BMI = body mass index; CRP = C-reactive protein; DBP 
= diastolic blood pressure; GFR = glomerular filtration rate; HDL = high-density lipoprotein; 
LDL = low-density lipoprotein; SBP = systolic blood pressure; ACE-I = angiotensin converting 
enzyme-inhibitor; ARB = angiotensin II receptor blocker; TG = triglycerides.
Variables Study group
Age (years) 60 (40-74)
BMI (kg/m2) 28.7 (25.8-29.7)
SBP (mmHg) 130 (120-144)
DBP (mmHg) 75 (70-83)
HbA1c (mmol/mol) 36 (34-39)
GFR (ml/min/1.7) 78 (69-87)
hs-CRP (mg/l) 0.56 (0.36-0.95)
fP-LDL (mmol/l) 1.4 (1.1-1.7)
fP-Cholesterol (mmol/l) 3.3 (2.6-3.4)
fP-TG (mmol/l) 1.0 (0.6-1.2)
Current smokers 3 (15)
Previous smokers 6 (30)
Aspirin 20 (100)
Statin 20 (100)
Betablocker 17 (85)
ACE-I 9 (45)
ARB 5 (25)
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Study outcomes
Effect of RIC on myocardial infarct size in patients with anterior STEMI (Studies I and II)
MSI based on infarct size and MaR from CMR was the primary endpoint to evaluate the 
effect of RIC in STEMI.  RIC did not significantly affect MSI as measured by CMR performed 
on day 4-7 (RIC group 48.5% vs control group 49.2%; p = 0.85) (Figure 11) or after six months 
(RIC group 67.1% vs control group 67.6%; p = 0.93) (Figure 12).
Figure 11.  MSI in Study I. MSI in the PCI group and the RIC + PCI group. Line and box mark 
median and interquartile range. Whiskers show min and max.  MSI = myocardial salvage 
index; PCI = percutaneous coronary intervention; RIC = remote ischemic conditioning.
Figure 12. MSI in Study II. MSI in the PCI group and the RIC + PCI group. Line and box mark 
median and interquartile range. Whiskers show min and max. MSI = myocardial salvage 
index; PCI = percutaneous coronary intervention. RIC = remote ischemic conditioning.
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Likewise, absolute infarct size and left ventricular function on acute and follow-up CMR was 
not different between the study groups. MaR was significantly larger in the RIC group as 
measured by CMR (43.1% vs 37.0% of the left ventricle; P = 0.03), but not when evaluated 
by BARI and modified APPROACH scores. Angiographic and CMR data are shown in Table 
VI and Table VII. Troponin T peak value (RIC group 5025 ng/l vs. control group 5350 ng/l; p 
= 0.73) and 44 h area under the curve (RIC group 55620 vs. control group 61560; p = 0.09) 
were not significantly affected by RIC. Exploratory subgroup analyses based on symptom 
to balloon time, culprit vessel, TIMI-flow grade in culprit vessel at presentation, number of 
RIC cycles or smoking status did not result in significant differences between study groups 
(Table VIII).
Table VI. Parameters from acute coronary angiography and CMR on day 4-7 in Study I. Data 
are presented as median and interquartile range or number of subjects and percentages. 
Significant differences were analyzed using Mann-Whitney U-test and Fisher’s exact test. 
BSA = body surface area; CMR = cardiac magnetic resonance; LV = left ventricle; LVEDV 
= left ventricular end-diastolic volume; LVEF = left ventricular ejection fraction; MSI = 
myocardial salvage index; RIC = remote ischemic conditioning.
Variables PCI (n=46) RIC+PCI (n=47) p 
Infarct size (% of LV) 17.9 (13.4-25.0) 20.6 (14.1-31.7) 0.26
MaR from CMR (% of LV) 37.0 (30.8-44.1) 43.1 (35.4-49.7) 0.03
MSI 49.2 (42.1-58.8) 48.5 (30.9-60.8) 0.85
LVEF (%) 50.1 (45.5-53.9) 48.1 (41.0-55.3) 0.24
LVEDV indexed for BSA (ml/m2) 89.4 (81.5-97.1) 90.0 (79.2-104.2) 0.74
LV mass indexed for BSA (g/m2) 78.0 (70.7-87.2) 81.1 (72.2-89.2) 0.62
Left ventricular thrombus 5 (11) 7 (15) 0.76
TIMI 3 flow after PCI 44 (96) 47 (100) 0.24
BARI score (% of LV) 33 (28-43) 38 (29-43) 0.28
Modified APPROACH score (% of LV) 32 (28-47) 32 (30-47) 0.30
Table VII. Parameters from CMR at six months in Study II. Median and interquartile range. 
Differences were analyzed with Mann-Whitney U-test. BSA = body surface area; LV = left 
ventricle; LVEDV = left ventricular end-diastolic volume; LVEF = left ventricular ejection 
fraction; LVESV = left ventricular end-systolic volume; MSI = myocardial salvage index; PCI 
= percutaneous coronary intervention; RIC = remote ischemic conditioning.
Variables PCI (n=40) RIC+PCI (n=36) P
Infarct size (% of LV) 11.6 (8.5-17.0) 14.2 (10.3-18.7) 0.23
Recovery of infarct size (% of LV) 6.6 (3.4-9.0) 7.5 (5.0-13.1) 0.31
MSI 67.3 (57.6-75.1) 67.9 (59.4-75.2) 0.93
LVEF (%) 56.5 (50.9-64.6) 53.2 (47.0-64.8) 0.29
Recovery of LVEF (% of LV) 8.5 (1.9-12.0) 7.3 (1.5-12.3) 0.45
LVEDV indexed for BSA (ml/m2) 93.6 (79.9-108.1) 93.6 (78.0-106.6) 0.73
LVESV indexed for BSA (ml/m2) 40.2 (28.3-51.9) 43.0 (29.3-55.6) 0.67
LV mass indexed for BSA (g/m2) 76.9 (69.1-88.1) 79.7 (68.8-90.5) 0.61
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Effect of RIC on clinical outcomes in patients with anterior STEMI (Studies I and II)
No patients died during primary PCI. Four patients in the RIC group and five patients in 
the control group died during the follow-up period of three years. Causes of death were 
myocardial infarction (four patients), cardiac arrest, heart failure, intracerebral hemorrhage, 
sepsis and esophageal cancer. Cardiac mortality, MACCE or the individual components of 
MACCE did not differ between the groups at 30 days (Table IX), six months (Table X) or three 
years (Table XI).
Table VIII. Myocardial salvage index in subgroups in Study I. Data are presented as median 
and interquartile range. Significant differences were analyzed using Mann-Whitney U-test. 
RIC = remote ischemic conditioning. N/A=not applicable.
Subgroup PCI RIC+PCI p
Non-smokers
n
49.7 (38.1-60.0)
32
45.4 (30.6-54.9)
26
0.37
LAD culprit vessel
n
49.7 (42.7-59.2)
43
48.5 (30.3-61.3)
45
0.56
Symptom to balloon time ≤145 min
n
48.7 (40.7-59.9)
22
54.4 (30.3-64.7)
25
0.95
Symptom to balloon time >145 min
n
49.7 (41.6-58.2)
24
46.9 (35.6-59.5)
22
0.65
TIMI-flow grade 0
n
48.3 (35.8-55.5)
34
46.3 (28.9-60.6)
36
0.81
<6 conditioning cycles
n
N/A 52.7 (32.8-71.7)
18
N/A
>7 conditioning cycles
n
N/A 52.3 (39.3-81.7)
27
N/A
Table IX. Clinical outcomes at 30 days in Study I. Number of patients and percentages. 
Differences were analyzed with Fisher’s exact test. MACCE = major adverse cardiac and 
cerebrovascular events; PCI = percutaneous coronary intervention; RIC = remote ischemic 
conditioning.
Variables PCI (n=55) RIC+PCI (n=60) P
MACCE 4 (7) 1 (2) 0.19
All-cause mortality 2 (4) 1 (2) 0.61
Cardiac mortality 2 (4) 1 (2) 0.61
Myocardial reinfarction 0 (0) 0 (0) 1.00
Target lesion revascularization 1 (2) 0 (0) 0.48
Readmission for heart failure 0 (0) 0 (0) 1.00
Ischemic stroke/transient ischemic attack 0 (0) 0 (0) 1.00
Use of iv diuretics during hospital stay 11 (21) 20 (34) 0.14
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Impact of exendin(9-39) on the effect of RIC on endothelial ischemia-reperfusion injury 
(Study III)
The degree of endothelial dysfunction in response to ischemia-reperfusion was determined 
in protocol A as the change in FMD from baseline. Ischemia-reperfusion impaired endothelial 
function (FMD at baseline 4.7 ± 0.8% vs. 1.5 ± 0.4% after ischemia-reperfusion; p <0.01) 
(Figure 13).
Table X. Clinical outcomes at 6 months in Study II. Number of patients and percentages. 
Differences were analyzed with Fisher’s exact test. MACCE = major adverse cardiac and 
cerebrovascular events; PCI = percutaneous coronary intervention; RIC = remote ischemic 
conditioning.
Variables PCI (n=54) RIC+PCI (n=59) P
MACCE 4 (7) 5 (9) 1.00
All-cause mortality 4 (7) 2 (3) 0.42
Cardiac mortality 3 (6) 1 (2) 0.35
Myocardial infarction 1 (2) 1 (2) 1.00
Target lesion revascularization 0 (0) 1 (2) 1.00
Readmission for heart failure 0 (0) 2 (4) 0.50
Ischemic stroke/transient ischemic attack 1 (2) 0 (0) 0.48
Table XI. Clinical outcomes at 3 years in Study II. Number of patients and percentages. 
Differences were analyzed with Fisher’s exact test. MACCE = major adverse cardiac and 
cerebrovascular events; PCI = percutaneous coronary intervention; RIC = remote ischemic 
conditioning.
Variables PCI (n=54) RIC+PCI (n=59) P
MACCE 9 (17) 8 (14) 0.79
All-cause mortality 5 (9) 4 (7) 0.73
Cardiac mortality 3 (6) 3 (5) 1.00
Myocardial infarction 3 (5) 2 (4) 0.66
Target lesion revascularization 1 (2) 2 (4) 1.00
Readmission for heart failure 1 (2) 3 (6) 0.62
Ischemic stroke/transient ischemic attack 1 (2) 0 (0) 0.49
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In protocol B, RIC during ischemia-reperfusion protected against this attenuation of FMD 
(baseline 4.6 ± 1.1% vs. 5.0 ± 1.2% after ischemia-reperfusion). In protocol C, simultaneous 
intravenous infusion of the GLP-1 receptor antagonist exendin(9-39) abolished the protection 
provided by RIC (FMD at baseline 4.9 ± 0.9% vs. 1.5 ± 1.3% after ischemia-reperfusion; p 
<0.01). Consequently, FMD after ischemia-reperfusion was significantly greater in protocol B 
(ischemia-reperfusion + RIC) than in protocol A (control ischemia-reperfusion) (p <0.05) and 
protocol C (exendin(9-39) + ischemia-reperfusion + RIC) (p <0.05). There was no difference 
in baseline brachial artery diameter or maximal flow rate during hyperemia between the 
protocols A-C (Table XII). EIVD of the brachial artery was not significantly different between 
the examinations. Plasma levels of insulin and GLP-1 were not significantly altered in any of 
the protocols (Table XIII).
Figure 13. Impairment of endothelial function following ischemia-reperfusion. FMD at 
baseline and following ischemia-reperfusion in protocol A, B and C. Mean values with 95% 
CI. Significant differences from baseline FMD within each protocol are depicted. **p<0.01; 
B = baseline; FMD = flow-mediated dilatation; I/R = ischemia-reperfusion; RIC = remote 
ischemic conditioning.
Table XIII. Plasma GLP-1 and insulin levels in Study III. Plasma GLP-1 and insulin levels be-
fore ischemia and during reperfusion. Values for GLP-1 are pmol/L and for insulin mIE/L. 
n=12. Means and SEM. GLP-1 = glucagon like peptide-1.
Protocol A Protocol B Protocol C
Plasma GLP-1
- Baseline 13.5 ± 3.1 11.8 ± 2.9 11.1 ± 2.9
- At reperfusion 14.2 ± 3.4 14.1 ± 3.0 13.6 ± 3.1
- 16 min after reperfusion 13.8 ± 3.5 12.3 ± 3.0 10.0 ± 2.2
Plasma insulin
- Baseline 6.4 ± 1.2 5.9 ± 0.7 6.4 ± 0.9
- 16 min after reperfusion 5.3 ± 0.9 7.0 ± 1.5 5.5 ± 0.6
Table XII. Brachial artery diameter and peak flow in Study III. Means and SEM. IR = 
ischemia-reperfusion; RIC = remote ischemic conditioning.
Protocol A Protocol B Protocol C
Variables Before IR After IR Before IR After IR Before IR After IR
Baseline diameter (mm) 3.6 ± 0.1 3.8 ± 0.1 3.5 ± 0.1 3.7 ± 0.1 3.5 ± 0.1 3.7 ± 0.1
Vpeak (cm/s) 58 ± 6 67 ± 5 66 ± 5 69 ± 5 61 ± 6 62 ± 4
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Effect of exendin(9-39) on endothelial function (Study III)
There was no effect of exendin(9-39) per se on basal endothelial function (FMD 4.1 ± 0.3% 
at baseline vs. 4.2 ± 0.5% after 40 minutes infusion), baseline brachial diameter (3.3 ± 0.1 vs. 
3.4 ± 0.1 mm) or maximal blood flow (57 ± 4.9 vs. 62 ± 4.8 cm/s). Furthermore, exendin(9-39) 
did not affect plasma glucose.
Effect of ticagrelor on endothelial function and ischemia-reperfusion injury (Study IV)
The effect of chronic ticagrelor treatment on basal endothelial function was evaluated 
by comparison of basal FMD between the visits. Chronic ticagrelor treatment was not 
associated with better basal endothelial function compared to after its discontinuation (Visit 
A: 3.2 ± 0.7 %; Visit B: 4.6 ± 0.8 %; Visit C: 2.3 ± 0.4 %; p=0.07). Ischemia-reperfusion caused 
significant impairment of endothelial function at all three visits. (Absolute change in FMD 
at Visit A: -3.0 (p<0.001), Visit B: -1.9 (p=0.03), Visit C: -1.9 (p<0.0001)). Ticagrelor did not 
confer protection against endothelial ischemia-reperfusion injury (p=0.39 for comparison 
between visits of absolute change in FMD after ischemia-reperfusion). (Figure 14).
The degree of endothelial impairment in response to ischemia-reperfusion did not differ 
significantly between the examinations. Baseline brachial artery diameter, maximal flow 
rate during hyperemia and EIVD of the brachial artery was not significantly different 
between the examinations (Table XIV). Trc-ADP confirmed a marked impairment of platelet 
function during ticagrelor treatment compared to after its discontinuation. Trc-ASPI was 
slightly lower at the first visit compared to the two following (Table XV).
Figure 14. Absolute change in FMD between baseline and after ischemia-reperfusion at 
each visit in Study IV. Bars mark mean and whiskers mark SEM. p=0.39 for comparisons 
between visits. FMD = flow-mediated dilatation. SEM = standard error of the mean.
Table XIV. Brachial artery diameter, peak flow and endothelium-independent vasodilata-
tion of the brachial artery from visits A-C in Study IV. Means and SEM. p>0.05 for compa-
risons within each variable. n=17. EIVD = endothelium-independent vasodilatation of the 
brachial artery; IR = ischemia-reperfusion.
Visit A Visit B Visit C
Variables Before IR After IR Before IR After IR Before IR After IR
Baseline diameter (mm) 3.8 ± 0.1 4.0 ± 0.1 3.9 ± 0.1 4.1 ± 0.1 4.0 ± 0.1 4.2 ± 0.1
Vpeak (cm/s) 48 ± 3 43 ± 3 43 ± 2 43 ± 3 47 ± 3 43 ± 3
EIVD (%) 14.3 ± 1.5 13.3 ± 1.7 12.1 ± 1.4
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Table XV. Platelet inhibition in Study IV. Means and SEM. Significant difference from visit 
A within each test is depicted. ****p<0.0001. *p<0.05. n=17.
Variable Visit A Visit B Visit C
Trc-ADP 23 ± 1.9 53 ± 3.9**** 53 ± 4.6****
Trc-ASPI 15 ± 1.7 23 ± 1.9* 22 ± 2.0*
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DISCUSSION
The concept of reperfusion injury has been extensively investigated since some 40 years. 
Although the precise underlying mechanisms are not fully understood, the therapeutic 
potential of therapies aimed at limiting reperfusion injury in STEMI is widely recognized. 
However, despite great scientific efforts and success in preclinical and early human studies, 
translation to clinical use has been cumbersome. Larger human trials exploring several 
different treatment strategies have not been conclusive and a therapy targeting reperfusion 
injury is yet to reach clinical guidelines. Nonetheless, RIC has emerged as a promising new 
approach, following the first trial of its effect in STEMI, demonstrating that RIC of the arm 
initiated during ambulance transport to the catheterization laboratory for primary PCI 
increased MSI 38. In the light of that landmark study, the present thesis was undertaken to 
investigate if a clinically feasible RIC-protocol initiated upon arrival in the catheterization 
laboratory provides cardioprotection in patients with STEMI treated with primary PCI and 
furthermore to explore underlying mechanisms of RIC. In order to bring additional insights 
into the signaling mechanisms behind RIC, the involvement of the GLP-1 receptor in the 
protective effect of RIC against ischemia-reperfusion injury in humans was determined. 
Finally, the potential influence of co-medication with ticagrelor on ischemia-reperfusion 
injury was investigated in patients with previous ACS. In a randomized trial of patients with 
anterior STEMI, we found that RIC as an adjunct to primary PCI does not limit infarct size or 
improve short-term or long-term clinical outcomes. In a mechanistic study of healthy male 
subjects we discovered the previously unknown mode of action of RIC to induce protection 
against endothelial ischemia-reperfusion injury in humans through a GLP-1 receptor 
dependent pathway. Furthermore, we found that chronic treatment with ticagrelor does 
not protect against endothelial ischemia-reperfusion injury or improve basal endothelial 
function in patients with a previous ACS.
Effect of RIC in STEMI
For the randomized trial of patients with STEMI we chose to study only patients with signs 
and symptoms of anterior STEMI, aiming to include patients with large MaR, thereby 
optimizing the power of the study. This strategy was supported by previous trials that 
have indicated that the effect of cardioprotective interventions aimed at limiting ischemia-
reperfusion injury may be most prominent in patients with large MaR38,158,161. We chose 
MSI as the primary endpoint as it evaluates infarct size relative to MaR, thereby limiting 
the impact of several factors (e.g. localization of coronary occlusion, temporal variation 
of degree of coronary occlusion and extent of collaterals) with the potential to affect the 
extent of ischemia and thereby absolute infarct size162. The influence of these factors 
increase the variability in infarct size of the study group resulting in the need of large 
sample sizes to detect significant differences in absolute infarct size. Therefore, using MSI 
as primary endpoint in our study with limited sample size was preferable. CMR was chosen 
as the modality to evaluate MSI as it allows to evaluate both MaR and infarct size in a single 
examination within a week from the myocardial infarction150. MaR was determined with 
early contrast-enhanced steady state free precession as it is a validated robust method, less 
sensitive to artifacts than T2-weighted analysis and has been used in previous multicenter 
trials and validated against SPECT107,150,163.
Dinos Verouhis
48
Although achieving a major proportion of patients with large MaR, relatively short symptom 
time (ensuring that a substantial part of the MaR was salvageable), good quality CMR with 
low intra-observer variation and low drop-out of study subjects, we found no effect of RIC 
on infarct size or clinical outcomes. Relative (MSI) and absolute (myocardial scar, troponin 
T release and left ventricular function) markers of infarct size were neutral between study 
groups in acute and long-term comparisons. Likewise, cardiac mortality, MACCE and all its 
individual components were not altered up to three years.
While our findings may appear inconsistent with those reported from previous studies of 
RIC in STEMI38-42,44-48,89,91, the different methodological designs and study endpoints used 
in the different trials complicate comparisons (Table I och Table II). Several studies have 
demonstrated an effect on surrogate markers of myocardial injury such as enzyme levels 
or ST-segment resolution39-42,44-47,91. However, the significance of such surrogate markers in 
the RIC-setting is unknown. Only the studies by White et al. and Liu et al. confirmed their 
findings of reduced enzymatic levels with a more robust marker of absolute infarct size, 
using CMR41,45. However, relying on measures of absolute infarct size may be troublesome in 
studies of limited sample size as several factors may influence infarct size independently of 
the intervention studied164-166. While some of those factors may be measured and adjusted 
for, other factors such as temporal variation of degree of coronary occlusion and extent 
of collaterals are more difficult to reliably detect. The resulting variability in infarct size 
affects the statistical power of the trial and may obscure the findings. Evaluating infarct size 
relative to MaR, to some extent overcomes these issues and increases statistical power167. 
Infarct size (CMR LGE images) analyzed relative to the extent of myocardial edema was 
not different between study groups in the trials of Crimi et al. and White et al., using T2-
weighted and T2-mapping techniques respectively for depiction of myocardial edema40, 
41. Interestingly, both the trial by Crimi et al. and the trial by White et al. found a smaller 
extent of myocardial edema on CMR in the groups treated with RIC than in the control 
groups, which led to the perception that the RIC intervention itself had reduced myocardial 
edema40,41. However, none of the trials were pre-specified for this endpoint. Nonetheless, 
a subsequent study in pigs found that RIC attenuated the extent of myocardial edema as 
measured by T2-weighted CMR168. Evaluation of MaR through T2-weighted and T2-mapping 
as well as early contrast-enhanced steady state free precession CMR sequences are edema-
based and it has therefore been suggested that intervention with RIC may reduce the extent 
of edema and thereby MaR determined with CMR169,170. Intriguingly, using early contrast-
enhanced steady state free precession CMR we noticed a larger MaR in the group treated 
with RIC. This was found to be associated to a larger proportion of proximal LAD occlusions 
in this group (50% more common), demonstrating the complexity in interpreting findings 
in this multifaceted research field. Furthermore, myocardial edema determined by CMR 
has also been argued to correlate better with the extent of myocardial infarction than with 
MaR171. Although these methods are validated and widely used to evaluate MaR, the above 
mentioned issues have questioned the appropriateness of their use to measure MaR in 
studies of cardioprotection105,110,169,170.
While the basic underlying idea of the effect of RIC against ischemia-reperfusion injury in 
STEMI is a reduction of the final myocardial infarct size, the use of different markers of 
absolute or relative infarct size as outcome measures is motivated from a pathophysiological 
viewpoint. Theoretically, this enables detection of relatively small treatment effects and 
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allows for smaller sample sizes than in studies based on clinical endpoints. However, it 
is important to remember that such endpoints in clinical trials are highly sensitive to the 
impact of several factors (e.g. localization of coronary occlusion, temporal variation of 
degree of coronary occlusion and extent of collaterals), which may affect the results in 
studies of limited sample size. Albeit more resource-intensive, using clinical endpoints of 
mortality and morbidity is preferable to properly determine the clinical value of RIC.
The trial by Gaspar et al. is the only one so far having clinical outcomes as the primary 
endpoint48. However, some inconsistency in the results challenge the interpretation of the 
trial. While having no impact on troponin I levels, RIC was associated with a reduction in 
combined two-year cardiac mortality and hospitalization for heart failure as well as for the 
individual components. However, there was no effect on two-year all-cause mortality or 
MACCE (defined as death, myocardial infarction, stroke, or target vessel revascularization). 
Furthermore, left ventricular function at one year was not affected, but an association 
between RIC and improvement of left ventricular function at one-year follow-up was 
observed in the subgroup of patients with the initially most severely impaired left ventricular 
function. Of potential importance is that the higher proportion of triple vessel coronary 
artery disease in the control group may have affected outcomes. Eitel at al. found no effect 
on clinical outcomes at six months follow-up in patients treated with combined RIC and 
local postconditioning43. However, Stiermaier et al. recently reported long-term data from 
the same trial, showing a reduced incidence of major adverse cardiac events (cardiac death, 
re-infarction and new congestive HF) after a median of 3.6 years follow-up90. This result was 
driven by a lower rate of HF. Clinical outcomes were also reported from the trial by Crimi et 
al., showing no difference between groups regarding death, stroke, myocardial infarction, 
repeated PCI or coronary artery bypass grafting at one year follow-up40. Likewise, MACCE 
(hospital admissions due to ACS, heart failure, cardiac rupture, cardiac death or stroke) at 
30 days were neutral between study groups in the trial by Yamanaka et al.44, as were major 
adverse cardiac events (all-cause mortality, nonfatal myocardial infarction, and target vessel 
revascularization) at six months in the trial by Elbadawi at al.46.
The most robust data supporting a cardioprotective effect of RIC in STEMI comes from the 
study by Bøtker et al.38. In spite of neutral results regarding troponin T levels, ST-resolution 
and myocardial scar, the primary outcome SPECT-based MSI was significantly larger in the 
group treated with RIC. A better left ventricular function within 24 hours of the intervention 
was noted. However, this difference did not persist after 30 days, at which time the incidence 
of major adverse coronary events likewise was equal between groups. Subgroup analysis 
showed that the effect of RIC on MSI was most evident in patients with large MaR and that 
this translated into better left ventricular function acutely, which persisted at 30 days161. 
A follow-up study (median time 3.8 years), found that MACCE (composite of all-cause 
mortality, myocardial infarction, readmission for heart failure and ischemic stroke/transient 
ischemic attack) was less prevalent in the RIC group89.
Comparing our study with that of Bøtker et al. it is important to keep in mind some key 
differences. Our study was the first to use early contrast-enhanced steady state free 
precession CMR in a trial of RIC in STEMI. However, this method has been validated against 
SPECT, used in the trial by Bøtker et al. Importantly, we performed the RIC-stimulus during 
late ischemia and early reperfusion (per-post remote ischemic conditioning) and used a 
higher number of conditioning cycles. While underlying mechanisms involved in mediating 
Dinos Verouhis
50
cardioprotection may differ when applying the RIC stimulus during late ischemia or 
early reperfusion57, experimental trials have confirmed the efficacy of a per-post remote 
ischemic conditioning protocol57, 124. However, it is possible that it is too late to perform 
part of the conditioning protocol after the onset of reperfusion in the clinical setting of 
STEMI. Additionally, it has been suggested that too many RIC cycles may result in deleterious 
hyperconditioning that may erase the benefits of RIC172. However, relevant experimental 
evidence supporting this concern is lacking and exploratory subgroup analysis in our study 
based on the number of RIC cycles performed showed no trend towards an effect of RIC 
in patients receiving fewer conditioning cycles. Furthermore, the trial of Bøtker et al. and 
ours were undertaken during a slightly different time period with inherent differences in 
baseline STEMI treatment, which may have affected the outcomes. Of special interest is 
that we used predominantly ticagrelor in addition to aspirin to achieve dual antiplatelet 
therapy, whereas the trial by Bøtker et al. used clopidogrel. In this aspect it is important 
to consider the pleiotropic actions of ticagrelor beyond platelet inhibition to inhibit cell 
reuptake of adenosine137 and the cardioprotective properties of adenosine139, 140. Thus, it is 
possible that patients were already receiving ticagrelor-induced cardioprotection, thereby 
masking a cardioprotective effect from RIC. Considering the proposed involvement of 
adenosine in mediating cardioprotection induced by RIC59, one may in fact speculate that 
the cardioprotective route of RIC was already being utilized in both study groups of our trial 
by the means of increased adenosine action induced by ticagrelor, thereby blunting the 
effect of RIC. However, the uptake and effect of an oral loading dose of ticagrelor in patients 
with STEMI may be delayed, especially when simultaneously treated with morphine, 
further complicating interpretation173. Additionally, morphine itself is associated with 
cardioprotective properties39, illustrating the intricacy of this field of research.
Collectively, data on the effect of RIC in STEMI remain inconclusive. While our study did 
not present support for its cardioprotective efficacy, the well-conducted landmark trial by 
Bøtker et al. argues the opposite. Considering the well acknowledged challenges of clinical 
studies in this field, further large scale clinical trials with appropriate endpoints are still 
warranted. Much awaited is the ongoing CONDI2/ERIC-PPCI (NCT02342522) multicenter 
trial randomizing more than 5000 patients with STEMI to a protocol of four cycles of upper 
arm RIC or sham procedure prior to primary PCI with cardiac death and hospitalization for 
heart failure as the primary outcome measure.
The GLP-1 receptor in RIC
While the cardioprotective potential of RIC in the ischemia-reperfusion setting is evident 
from numerous animal studies, the overall results from clinical trials so far have not been 
fully as conclusive. This has stressed the importance of decoding the mode of action of 
RIC. The startling transfer of the conditioning signal from remote tissue to end-organ has 
been intensely explored and several possible pathways have been proposed. Sectioning of 
the spinal cord, the vagal, the sciatic or the femoral nerves50,55-57 abolishes cardioprotection 
provided by RIC, indicating the involvement of a neural route of transfer of the conditioning 
signal. This is further supported by the findings that the effect of RIC is inhibited by the 
muscarinic cholinoreceptor blocker atropine50 and the autonomic ganglion blockers 
hexamethonium35 and trimetaphan37. However, there is also strong evidence for the existence 
of a humoral route based on the finding that the isolated Langendorff-perfused heart is 
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protected by dialysate from a donor treated with RIC61. Remarkably, this is valid even across 
species64,174,175. Intriguingly, the effect is lost if the donor has undergone bilateral vagotomy53, 
if the dialysate comes from a patient with diabetic neuropathy49 or if the recipient heart is 
administered atropine or hexamethonium53. Collectively, these findings indicate an interplay 
between humoral and neural mechanisms to elicit end-organ protection from the remote 
stimulus. However, the site and mode of such interaction has not been identified.
In a recent study in rats it was demonstrated that selective sectioning of the posterior 
gastric branch of the vagal nerve abolishes cardioprotection from RIC, while stimulation of 
the same branch mimics the protection induced by RIC69. Subsequently, the hypothesis was 
raised that activation of the posterior gastric branch of the vagal nerve leads to release of a 
cardioprotective humoral factor from visceral organs receiving innervation from this branch. 
While several gut hormones could be potential candidates, most attention was directed 
towards the incretin peptide hormone GLP-1. GLP-1 has been increasingly appreciated for 
its cardioprotective virtues in patients with diabetes mellitus176,177. Importantly, the use of 
GLP-1 receptor agonists has appeared as one of the currently most promising approaches to 
pharmacologically limit ischemia-reperfusion injury after two trials demonstrating smaller 
infarct size and better left ventricular function in patients with STEMI by the administration 
of the GLP-1 receptor agonist exendin-4 as an adjunct to standard therapy including primary 
PCI75,76. Somewhat puzzling, a similar approach did not result in smaller infact size in another 
recent study178. Nontheless, in a rat model it was demonstrated that the GLP-1 receptor 
inhibitor exendin(9-39) abolishes RIC-induced cardioprotection179. Plasma GLP-1 levels 
were moderately increased in response to RIC. Furthermore, it was shown that systemic 
administration of the GLP-1 receptor agonist exendin-4 mimics the cardioprotective effect 
of RIC through an M3 muscarinic receptor-dependent mechanism which is insensitive to 
bilateral cervical vagotomy.
Based on these findings, Study III was conducted. The impact of GLP-1 receptor inhibition on 
the protective effect of RIC against endothelial ischemia-reperfusion injury was evaluated 
in healthy males to avoid the possible confounding effect of comorbidities, co-medication 
and menstrual cycle180,181. Albeit limiting the generalizability of the results, this study design 
was chosen as it served the purpose of exploring the signaling mechanisms behind RIC. 
Endothelial ischemia-reperfusion injury as evaluated by FMD was used as effect measure as 
it is a validated model for such investigations123. We could in this study confirm that ischemia-
reperfusion is associated with a marked impairment of endothelial function. The study clearly 
demonstrated that intravenous infusion of the GLP-1 receptor antagonist exendin(9-39) 
abolishes the protective effect of RIC against endothelial ischemia-reperfusion injury. While 
subsequent studies need to confirm that this mechanism is present also in myocardial 
ischemia-reperfusion injury in humans, our findings propose a possible link between the 
neural and humoral mechanisms involved in mediation of the conditioning signal elicited 
by RIC. Study III was not designed to identify the specific mode of such an interaction. 
Nonetheless, combining our results with those of previous studies may suggest that RIC 
induces vagal activation, leading to the release of GLP-1 from intestinal L-cells to further 
relay the conditioning signal. However, the precise site of action of GLP-1 is still unclear. GLP-
1 receptors are widely present in the body and abundant research has demonstrated their 
involvement in complex signaling pathways including the central neural system and various 
peripheral organs182. It has been shown that GLP-1 improves endothelial function via a GLP-1 
receptor dependent mechanism183-185, indicating that RIC may induce end-organ protection 
through the effect of systemic GLP-1 acting on the endothelium. However, forearm blood 
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flow is not increased by intra-arterial infusion of GLP-1 in healthy subjects186. Although not 
statistically significant, the small increase (20%) in plasma GLP-1 in Study III was comparable 
to that in rats experiencing GLP-1 receptor dependent cardioprotection from RIC179. The 
subtle change in plasma GLP-1 level in response to RIC in Study III makes it rather unlikely 
that the effect on the endothelium in this trial comes from circulating GLP-1. Another 
conceivable mechanism is that GLP-1 released from intestinal L-cells or at another, yet 
unidentified, site in the periphery stimulates GLP-1 receptors on vagal afferents, propagating 
the conditioning signal to the central nervous system, where it is further relayed towards end-
organ protection. Interestingly vagal afferent fibers carrying GLP-1 receptors are involved in 
such neuroincretin circuits to control blood glucose levels and food intake187. Furthermore, 
the possible involvement of GLP-1 released locally in the central nervous system (perhaps 
as part of a vagal loop) to further communicate the conditioning signal needs to be taken 
in to account. Apart from being an incretin, GLP-1 is also an important neurotransmitter, 
released primarily in the solitary nucleus of the brainstem188. While predominantly explored 
for its metabolic effects, intracerebroventricular infusion of exendin-4 also increases heart 
rate and blood pressure through a pathway dependent on the vagal nerve, demonstrating 
the potential significance for cardiovascular effects189. Additionally, in a mouse model it 
was recently shown that the GLP-1 receptor agonist exendin-4 controls cardiac ventricular 
excitability in Langendorff-perfused hearts in an Ach and NO mediated manner, indicating 
the presence of GLP-1 receptors on efferent vagal neurons at the intrinsic cardiac ganglia190. 
Thus, it is conceivable that GLP-1 may in fact exert cardioprotection through dual pathways, 
involving receptors in the periphery as well as in the central nervous system and that RIC 
may activate one or both of those pathways. Interestingly, an additive cardioprotective 
effect of exendin-4 to RIC has been demonstrated in pigs191. These findings are indeed 
being further explored in the ongoing very interesting COMBAT-MI trial (NCT02404376) 
randomizing 428 patients with STEMI undergoing primary PCI to placebo, RIC, the GLP-1 
receptor agonist exenatide or the combination of RIC and exenatide. In fact, the concept of 
providing cardioprotection through multitargeted approaches is currently gaining increased 
attention192.
Figure 15. Proposed neurohormonal link for transmission of cardioprotective signal in RIC. 
RIC performed during ischemia-reperfusion initiates a cardioprotective interplay involving 
activation of the vagal nerve and the GLP-1 receptor and ultimately terminating in end-
organ protection. GLP-1 = glucagon-like peptide-1; RIC = remote ischemic conditioning.
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To summarize, the results of Study III demonstrate that RIC exerts end-organ protection 
through a GLP-1 receptor-dependent mechanism and, combined with data from previous 
studies, propose the vagal nerve as a link between humoral and neural pathways involved 
in mediating the effects of RIC (Figure 15). However, the precise underlying structure of this 
mechanism is unclear and requires further exploration.
Effect of ticagrelor treatment on the endothelium
The effect of chronic ticagrelor treatment was evaluated in a clinically relevant cohort 
of patients with a previous ACS, thereby strengthening the generalizability of the study. 
Analyzing the degree of platelet inhibition with Multiplate (Roche Diagnostics) allowed us 
to confirm patient adherence to treatment and discontinuation. Using a validated model 
based on FMD123, we found that in patients with a previous ACS, long-term treatment with 
ticagrelor is not associated with protection against ischemia-reperfusion injury or better 
endothelial function compared to after its discontinuation.
Over the last decade there has been increasing interest for the pleiotropic effects of 
ticagrelor, possibly contributing to cardioprotection. In the PLATO-trial, ticagrelor was 
associated with better cardiovascular outcomes and survival compared to clopidogrel134. 
The precise underlying mechanism for this superiority of ticagrelor has not been confirmed, 
but studies in rats141,142, pigs143 and dogs193 have shown that despite a similar degree of 
platelet inhibition, treatment with ticagrelor reduces infarct size after myocardial ischemia-
reperfusion to a greater extent than treatment with clopidogrel, indicating a pleiotropic 
cardioprotective effect. Apart from being a P2Y12 receptor blocker, ticagrelor also increases 
extracellular adenosine levels through inhibition of the equilibrative nucleoside transporter 
1 (ENT1)137, leading to impeded uptake of adenosine in erythrocytes. When exposed to 
ischemia-reperfusion, ENT1-null mice are cardioprotected in an adenosine-dependent 
manner compared to wild type animals, indicating a therapeutic potential of this pathway194.
Adenosine itself has received much attention for its possible cardioprotective properties. 
Although trials of adenosine as an adjunct to reperfusion therapy in STEMI have provided 
conflicting evidence of its efficacy, the comparison of these studies has been complicated 
by their differing designs (e.g. mode of adenosine administration and dose, mode of 
reperfusion, ischemic time)195. Much encouraging, a large meta-analysis found evidence for 
a cardioprotective effect of intracoronary adenosine in addition to primary PCI in STEMI140. 
However, a recent randomized trial of intracoronary adenosine in addition to primary PCI in 
STEMI, showed not only lack of cardioprotection, but also a higher rate of adverse clinical 
outcomes in the adenosine treated group, further complicating the interpretation of the 
possible effect of adenosine in STEMI196. Collectively these findings highlight the need to 
better understand underlying mechanisms of adenosine in ischemia-reperfusion to tailor 
future clinical studies adequately to unravel the potential role of adenosine in STEMI. This 
may also be of importance to fully understand the cardioprotective properties of ticagrelor, 
in the light of previous studies indicating an important involvement of adenosine. 
A loading dose of ticagrelor in patients with ACS induced a significant increase in plasma 
adenosine levels compared to a loading dose of clopidogrel and this effect was related to 
inhibition of adenosine uptake by erythrocytes138. In healthy subjects a loading dose of 
ticagrelor was shown to induce adenosine-mediated increase in coronary blood flow197. 
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Pigs receiving a loading dose of ticagrelor before myocardial ischemia-reperfusion suffered 
a significantly smaller myocardial infarction than if loaded with clopidogrel, despite 
equal degree of platelet inhibition and this effect was adenosine receptor dependent143. 
Furthermore, chronic (7 days) ticagrelor treatment before myocardial ischemia-reperfusion 
in rats dose-dependently reduced infarct size in an adenosine receptor-dependent manner 
including downstream activation of eNOS and cyclooxygenase-2141. Clopidogrel treatment 
(7 days) had no such effect despite similar degree of platelet inhibition. Studies of patients 
with longer duration of ticagrelor treatment have yielded conflicting results. Patients with 
a previous ACS receiving ticagrelor for three to twelve months had better endothelial 
function than a control group on chronic clopidogrel or prasugrel treatment198. Ticagrelor 
treatment for 30 days improved endothelial function compared to clopidogrel in patients 
with a previous ACS and this was correlated to a significant increase in plasma adenosine 
levels199. In contrast, four weeks of treatment with ticagrelor in patients with a previous 
ACS was not associated with improvement in endothelial function compared to treatment 
with clopidogrel or prasugrel200. Additionally, plasma adenosine levels were unaffected. 
Similarly, termination of ticagrelor treatment after one year in patients with a previous 
ACS did not result in deterioration of endothelial function201. However, this assessment was 
performed within five days after cessation of ticagrelor treatment. Furthermore, in patients 
with stable coronary disease, plasma adenosine levels were not affected after 30 days of 
ticagrelor treatment compared to 30 days of clopidogrel treatment202. To summarize, there 
is robust support for the superiority of ticagrelor over clopidogrel for clinical outcomes in 
patients with ACS, despite similar degree of platelet inhibition between the compounds, 
indicating a pleiotropic effect of ticagrelor of clinical significance. Available experimental 
data supporting the idea that ticagrelor exerts an adenosine receptor dependent protection 
against myocardial ischemia-reperfusion injury come from animal studies, while previous 
mechanistic trials in humans have only investigated basal endothelial function per se and 
results are not conclusive.
Studies I and II were the first to evaluate the effect of RIC in STEMI in patients receiving 
predominantly ticagrelor in addition to aspirin to achieve double antiplatelet therapy. 
Considering the neutral outcome of those studies as opposed to the findings of the trial of 
Bøtker et al.38, (where patients mainly received clopidogrel in addition to aspirin) it is worth 
contemplating whether patients in Studies I and II were already receiving cardioprotection 
through pleiotropic effects of ticagrelor. Thereby, the impact of further cardioprotection 
by RIC may have been blunted. Interestingly, there is support for the involvement of 
adenosine in mediating cardioprotection induced by RIC59. Thus, it is conceivable that the 
cardioprotective route via remote ischemic conditioning was already activated in both 
study groups by the means of increased adenosine action induced by ticagrelor. These 
considerations led us to conduct Study IV.
Study IV was the first to investigate the effect of ticagrelor on an established model of 
ischemia-reperfusion injury in humans. The demonstrated lack of protection against 
ischemia-reperfusion injury contrasts the findings of previous animal studies and illustrates 
the well-known translational challenges associated with research in cardioprotection203. 
Furthermore, discontinuation of chronic ticagrelor treatment did not result in decline in 
endothelial function per se. While this supports the findings of one previous trial201, our 
study examined the subjects with a longer interval after cessation of ticagrelor and longer 
intervals between examinations, ruling out any possible lingering effect of the medication 
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(additionally confirmed by measurements of platelet inhibition) or conditioning state from 
previous examinations. Study IV adds substantial knowledge to the growing understanding of 
the pleiotropic effects of ticagrelor and its possible implications. Importantly, it contributes 
to the understanding of two major current cardiological dilemmas:
What is the optimal duration of ticagrelor treatment after STEMI? Primarily founded on 
the results of one large randomized trial showing a modest risk-benefit gain of prolonged 
treatment135, current ESC Guidelines for the duration of dual antiplatelet therapy give a weak 
recommendation (IIb) for considering extended treatment with ticagrelor beyond twelve 
months after an ACS to patients with high ischemic and low bleeding risk133. Underlying 
mechanisms for this prolonged protection are not clear, but pleiotropic properties of 
ticagrelor beyond platelet inhibition have been suggested136. Defining the clinical significance 
of the pleiotropic effects of ticagrelor could be helpful to tailor its use. The findings of Study 
IV do not give support for the notion that long term treatment with ticagrelor improves 
endothelial function or protects against ischemia-reperfusion injury in patients with a 
previous ACS.
Does co-medication with ticagrelor interfere with the effect of cardioprotective 
interventions? The impact of co-medication in the translational dilemma of cardiovascular 
research is receiving increasing attention204. The possible adenosine receptor dependent 
cardioprotective effect of ticagrelor has been suggested to conceal cardioprotective effects 
of other interventions, such as in our own previous study of remote ischemic conditioning 
as an adjunct to primary PCI in patients with STEMI. However, the findings of Study IV do 
not give support to the idea that long term treatment with ticagrelor affects ischemia-
reperfusion injury in humans with established coronary artery disease.
Limitations
It was not possible to blind the RIC procedure to patients, interventionalists or FMD 
examinators. However, the analyses of FMD examinations and CMR images were performed 
by investigators blinded to randomization. We did not perform core lab analysis of CMR 
examinations. However, all CMR images were independently assessed by two investigators 
(one with level III CMR certificate) and intra-observer variability was low. Limb ischemia in the 
individual study subjects undergoing RIC was not verified. However, pilot investigations on 
healthy subjects confirmed loss of peripheral pulsations verified with Doppler with inflation 
of the lower limb cuff. The number of patients included in Studies I and II was based on a 
sample size calculation for the primary endpoint of Study I (MSI). Thus analyses of clinical 
outcomes must be cautious. There was an 18 % loss of follow-up of CMR examinations 
between Study I and Study II. However, loss to clinical follow-up was low. The generalizability 
of the findings in Studies III and IV is limited by the choice to include only men. Only the effect 
of chronic ticagrelor treatment and its discontinuation was investigated and no extrapolation 
to the effects of a bolus dose of ticagrelor in the acute STEMI setting can be done. Basal FMD 
and endothelial ischemia-reperfusion injury in ticagrelor-naïve patients were not evaluated. 
Plasma adenosine was not measured and we are therefore unable to correlate results to 
the ability of chronic ticagrelor treatment to affect plasma adenosine levels. Plasma levels 
of ticagrelor were not measured. However, analyses of ticagrelor-specific platelet inhibition 
confirmed compliance to ticagrelor and then discontinuation as intended.
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Concluding remarks and future perspectives
Despite intense efforts over the last decades and striking efficacy in a large number of 
studies of myocardial ischemia-reperfusion injury in animals as well as in human surrogate 
models, clinical studies of patients with STEMI have still not gathered enough support to 
bring RIC into clinical practice. Several possible reasons for this merit discussion.
The evidence for the mere existence of ischemia-reperfusion injury are from in vitro and animal 
studies. While there is data supporting specific pathophysiological mechanisms contributing 
to reperfusion injury, it is difficult to distinguish myocardial ischemic from reperfusion injury 
in the individual subject. The firmest evidence for the existence of reperfusion injury come 
from the concept that interventions applied after the moment of reperfusion may alter 
the extent of cardiomyocyte death. Although this concept is widely accepted it is valid 
to note the possibility that the intervention may be targeting reversible cardiomyocyte 
injury related to the ischemic trauma irrespective of the reperfusion. Nonetheless, from a 
pragmatic point of view this difference may be of subordinate importance. An intervention 
with the potential to limit the extent of myocardial injury is worth exploring regardless 
of its specific pathophysiological target. While findings from animal studies strongly 
support the actuality of reversible myocardial ischemia-reperfusion injury, the collective 
experience from human studies has been more difficult to interpret. Experimental studies 
using therapeutic intervention in different models of ischemia-reperfusion injury (such as 
endothelial ischemia-reperfusion injury in Studies III and IV of this thesis) give support for 
the existence of reversible ischemia-reperfusion injury in humans. However, it is important 
to remember that these are surrogate models of myocardial ischemia-reperfusion injury. 
Results in studies of interventions against myocardial ischemia-reperfusion injury in humans 
have been less consistent. Considering the relatively large number of different approaches 
to limit ischemia-reperfusion injury that have proven highly efficient in animal studies but 
rather disappointingly have failed to show a clear effect in clinical human trials of myocardial 
ischemia-reperfusion injury, it seems appropriate to keep in mind that this may in fact 
indicate a misconception of pathophysiological target.
Additional factors may explain the translational challenges from animal and experimental 
human studies to human clinical trials. There are fundamental differences in the 
pathophysiological mechanisms investigated. In animal studies of myocardial ischemia, 
coronary occlusion is essentially a purely mechanical procedure, while patients with STEMI 
typically undergo a more complex multifactorial process including thrombotic activation, 
inflammation and distress. Additionally, unlike experimental animals, patients with STEMI 
are often elderly with concomitant diseases and various ongoing medications. These are 
major issues, when considering the translational dilemmas. Advanced age205, diabetes 
mellitus206, acute hyperglycemia207 and hypercholesterolemia208 have been demonstrated to 
impair cardioprotection from RIC. Additionally, co-medication may affect results in clinical 
trials of RIC209. Interpretation of experimental human studies using surrogate endpoints for 
myocardial ischemia-reperfusion injury such as endothelial ischemia-reperfusion injury are 
hampered by several factors. Subjects are typically examined in a very different setting to 
that of STEMI (thrombotic activation, inflammation, distress etc.). The relevance of using 
surrogate endpoints such as endothelial ischemia-reperfusion injury may be limited since it 
has not been possible to clearly validate them to human myocardial ischemia-reperfusion 
injury. It is unclear whether mechanisms protecting against non-myocardial ischemia-
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reperfusion injury are relevant for cardioprotection. Furthermore, there is substantial 
variation in several important details in STEMI. The presence of pre-infarction angina, extent 
of collaterals, co-medication, variability of oxygen demand during ischemia, duration of 
ischemia and temporal variation of coronary occlusion until final reperfusion may all affect 
final infarct size. Some of these variables are possible to measure to some extent, while 
other are virtually impossible to detect and thus adjust for. Several of these factors may 
affect the effect of cardioprotective measures and thus have an impact on the results of 
clinical studies in humans. Finally, trials of RIC in patients with STEMI have so far mainly 
aimed to evaluate the effect on myocardial infarct size using different markers of myocardial 
injury. As the complexity of STEMI makes absolute infarct size highly susceptible to several 
important confounders, evaluating infarct size relative to MaR is to prefer. CMR has been 
validated against the golden standard SPECT and has the advantage of allowing evaluation 
of infarct size and MaR in a single examination within a week from the myocardial infarction. 
While it has gained increasing popularity also in studies of RIC in STEMI, its validity in this 
field of research has been questioned. CMR uses myocardial edema as a surrogate for MaR 
and it is not certain whether RIC itself affects myocardial edema or not.
To conclude, the effect of RIC in patients with STEMI remains to be confirmed. Future studies 
should evaluate infarct size based on robust markers of myocardial injury. Most appropriate 
methods are currently CMR and SPECT. Considering the complex heterogeneity of STEMI, 
evaluation of absolute infarct size is sensitive to the impact of several possibly confounding 
factors, thus requiring large sample sizes. Evaluating infarct size relative to MaR allows for 
smaller sample sizes, but controversies of validity (CMR) and availability (SPECT) may trouble 
such approaches. Development of a method with the capability to reliably discriminate 
myocardial injury due to reperfusion from that due to ischemia could dramatically change 
the preconditions for this field of research. The concept of multitargeted cardioprotective 
approaches may provide new possibilities to establish efficient therapies against ischemia-
reperfusion injury.
While this thesis illustrates the translational challenges and complexity of research in the field 
of myocardial ischemia-reperfusion injury, it points to the need for deeper understanding of 
the underlying mechanisms of ischemia-reperfusion injury and RIC as well as for large scale 
clinical trials powered for hard clinical endpoints to fully determine the value of RIC in STEMI. 
Furthermore, a novel pathway involved in RIC in humans is presented, possibly linking the 
humoral and neural pathways together and providing the basis for further experimental 
studies to disclose the underlying mechanisms of RIC.
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CONCLUSIONS
1. RIC as an adjunct to primary PCI in patients with STEMI does not confer 
cardioprotection.
2. RIC protects against endothelial ischemia-reperfusion injury through a GLP-1 
receptor dependent pathway in humans.
3. Chronic treatment with ticagrelor does not confer protection against endothelial 
ischemia-reperfusion injury in patients with a previous ACS.
4. Chronic treatment with ticagrelor is not associated with better endothelial function 
than after its discontinuation in patients with a previous ACS.
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